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Abstract 
Obesity is a serious problem in society today [1,2]. It might seems to have been caused 
simply by excess consumption of food compared to energy expenditure but obesity is actually 
a complex metabolic disorder centred on adipose lipid metabolism and cellular signalling 
systems linked to it [3]. Understanding the biology of adipose tissue (AT) is very important 
for the identification of novel and potential therapeutic targets in order to prevent and treat 
obesity-related disorders [4]. We utilized analytical approach liquid chromatography coupled 
to mass spectrometry (LC-MS) to study adipose tissue metabolism. Also, we were especially 
interested in the effect of omega-3 polyunsaturated fatty acids (PUFA) on that metabolism. 
Rodent and cell line experiments were performed and analyses were done of white adipose 
tissue (WAT), serum/plasma samples or cells as well as milk samples from mothers.  
At first, we established several ultra performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS) methods for analysis of acylcarnitines (AC), amino acids 
(AmA) and other metabolites. Importantly, these methods were able to distinguish isobaric 
species of AC which is not usually possible. Using these approaches we uncovered several 
acylcarnitines, i.e. long chain AC, carnitine, acylcarnitine C4 and C6, C4DC, as well as amino 
acids tyrosine, alanine, ornithine and threonine that could serve as complex, gender-specific 
biomarkers of propensity to obesity and partially as a biomarker of obesity-associated insulin 
resistance. It was discovered that maternal intake of a cafeteria diet during lactation in rats 
alters in the plasma profile of AC and AmA. Specifically, it was noticeable in acetylcarnitine 
and medium- and long-chain AC, as well as glycine, alanine, isoleucine, serine and proline, in 
the offspring.  
Second, we focused on mutual interaction between two main cell types of adipose 
tissue, adipocytes and adipose tissue macrophages. Our results showed that macrophages 
modulate lipolysis and fatty acid re-esterification in adipocytes while their modulation 
depends on polarization states of macrophages and responses to dietary omega-3 PUFA 
supplementation. Then UPLC-MS/MS metabolomic method revealed that inflammatory M1 
and anti-inflammatory M2 macrophages act differently. This thesis also explores lipid 
mediators synthesized in adipose tissue. As a result, the origin of lipid mediator protectin D1 
was discovered. Also, levels of several lipid mediators in different cell types of WAT were 
determined and showed interplay between them. Moreover, we documented the             
omega-3 PUFA´s ability to lower the inflammation in WAT.  
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Later on, we concentrated on branched fatty acid hydroxy fatty acids (FAHFA) lipid 
molecules that influence WAT metabolism as well. We identified a novel compound of 
FAHFA lipid class, docosahexaenoic acid hydroxylinoleic acid (DHAHLA), by its 
fragmentation scheme and detected several DHAHLA´s isomers in murine serum. We then 
demonstrated that adipocytes and macrophages are able to synthetize 13-DHAHLA and we 
proved its anti-inflammatory and pro-resolving properties. Subsequently, we found               
13-DHAHLA in human breast milk for the first time but only in samples from mothers who 
were supplemented with omega-3 PUFA during pregnancy. It is also important to indicate 
that FAHFA from breast milk reach a newborn‘s circulation and thus potentially positively 
influence its metabolism.  
In summary, we used very sensitive UPLC-MS/MS methodology to broaden our 
knowledge on adipose tissue metabolism. Specifically, we focused on mutual interaction 
between main components of adipose tissue and we analysed different metabolites 
(e.g. acylcarnitines, lipid mediators, FAHFA compounds) that influence adipose tissue 
metabolism in various samples.  
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Abstrakt 
V současné době je obezita vážný problém [1,2]. Ačkoliv by se mohlo zdát, že jde 
pouze o vyšší příjem potravy oproti energetickému výdeji, jde o složitou metabolickou 
chorobu, která se váže na lipidový metabolismus v tukové tkáni a buněčnou signalizaci s ním 
spojenou [3]. Je velmi důležité porozumět biologii tukové tkáně, abychom mohli rozpoznat 
nové a potencionální terapeutické cíle, které by nám pomohly předcházet a léčit choroby 
spojené s obezitou [4]. V našem výzkumu jsme využili především analytickou techniku 
kapalinové chromatografie s hmotnostní spektrometrií (LC-MS) ke studiu metabolismu 
tukové tkáně a rovněž jsme se zaměřili na vliv omega-3 polynenasycených mastných kyselin 
(PUFA) na tento metabolismus. Prováděli jsme pokusy na hlodavcích a buněčných liniích 
a analyzovali jsme bílou tukovou tkáň, vzorky séra/plasmy, buněk a mateřského mléka.  
Nejprve jsme zavedli několik metod ultraúčinné kapalinové chromatografie 
s tandemovou hmotnostní detekcí (UPLC-MS/MS) k analýze acylkarnitinů (AC),  
aminokyselin (AmA) a dalších metabolitů. Tyto metody nám umožnily rozdělit isobarické 
acylkarnitiny, ačkoliv to není obvykle možné. Použití těchto metod také odhalilo několik 
acylkarnitinů, t.j. AC s dlouhým řetězcem, karnitin, acylkarnitiny C4 a C6, C4DC stejně tak 
jako aminokyseliny tyrosin, alanin, ornithin a threonin, které by mohly sloužit jako komplexní 
pohlavně specifické biomarkery náchylnosti k obezitě a k obezitou podmíněné inzulínové 
rezistenci. Navíc jsme odhalili, že příjem vysokotukové diety kojících krysích samic vede 
ke změnám v profilu AC a AmA v plasmě mláďat. Konkrétně jde o acetylkarnitin, AC se 
středně dlouhými a dlouhými řetězci a glycin, alanine, isoleucine, serin a prolin.    
Poté jsme se zaměřili na vzájemné interakce dvou hlavních typů buněk v tukové tkáni, 
adipocytů a makrofágů tukové tkáně. Naše výsledky ukázaly, že makrofágy specificky mění 
lipolýzu a re-esterifikaci mastných kyselin v adipocytech, přičemž tyto změny závisí na 
polarizačním stavu makrofágů a jsou odpovědí na suplementaci omega-3 PUFA v dietě. Dále 
jsme s využitím UPLC-MS/MS metabolomické metody odhalili, že se prozánětlivé M1 
a protizánětlivé M2 makrofágy chovají rozdílně. V další části dizertační práce jsme zkoumali 
lipidové mediátory, které vznikají v tukové tkáni. Zjistili jsme původ lipidového mediátoru 
protektinu D1. Také jsme stanovili hladiny několika dalších lipidových mediátorů v různých 
buněčných typech tukové tkáně a ukázali jsme jejich vzájemné působení. Navíc jsme doložili 
schopnost omega-3 PUFA snížit zánět v tukové tkáni.   
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Následně jsem se zaměřili na větvené estery oxidovaných mastných kyselin (FAHFA) 
lipidové molekuly, které rovněž ovlivňují metabolismus tukové tkáně. Popsali jsme novou 
sloučeninu z této lipidové třídy, t.j. ester kyseliny dokosahexaenové a hydroxylinolové 
(DHAHLA), pomocí fragmentačních schémat a detekovali jsme několik jejích izomerů           
v myší plasmě. Poté jsme ukázali, že jsou adipocyty a makrofágy schopné vytvořit                  
13-DHAHLA a dokázali jsme její protizánětlivé účinky. Následně jsme jako první odhalili 
výskyt 13-DHAHLA v mateřském mléce, ale pouze ve vzorcích od matek, které během 
těhotenství užívaly omega-3 PUFA suplementaci. Naše výsledky rovněž naznačují, že se 
molekuly FAHFA z mateřského mléka mohou dostat do oběhu novorozence a tak pozitivně 
ovlivnit jeho metabolismus.   
Závěrem lze řící, že jsme s využitím velmi citlivé techniky UPLC-MS/MS rozšířili 
naše znalosti o metabolismu tukové tkáně. Konkrétně jsme se zabývali vzájemnou interakcí 
mezi hlavními složkami tukové tkáně a analyzovali jsme různé metabolity 
(např. acylkarnitiny, lipidové mediatory, FAHFA sloučeniny) v různorodých vzorcích, které 
tento metabolismus ovlivňují.  
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1. THEORY 
 
1.1. BIOLOGY 
 
1.1.1. Obesity 
 
Nowadays the obesity is a serious problem even in childhood and in adolescence. 
Obesity is defined as a body mass index (BMI) of 30 and higher [2] while BMI represents an 
index of an individual‘s fatness [5]. BMI is calculated as weight divided by height squared [6] 
and it is used for classifying (categorizing) adults into groups (see Figure 1) [5]. 
Unfortunately, there is a positive association between the body mass index and the risk of 
type 2 diabetes (T2D) [1]. Up to 51.6% of adults people were over-weight in 2014 in 
EU (35.7% pre-obese and 15.9% obese). The lowest level of obesity among the adult 
population was in Romania (9.4%) and Italy (10.7%) while Malta was at the opposite side of 
the scale (26.0%) in the same year. The Czech Republic belongs to states with relatively high 
number of obese people, as there are 19.3 % of obese men. Interestingly, it has been shown 
that obesity is closely connected with the age of population and their education level because 
the older and lower the education level in population, the more cases of obesity were 
found [2].  
Categories BMI 
Underweight 15-19.9 
Normal weight 20-24.9 
Overweight 25-29.9 
Preobesity  
Class I obesity 30-34.9 
Class II obesity 35-39.9 
Class III obesity ≥40 
Figure 1. Categories of body mass index (BMI). Adapted from [5]. 
 
It might seem to have been caused simply by excess consumption of food compared to 
energy expenditure but obesity is actually a complex metabolic disorder centred on adipose 
lipid metabolism and cellular signalling systems linked to it [3]. Obesity results in ectopic 
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accumulation of lipids, release of pro-inflammatory molecules from white adipose tissue into 
circulation [7] and it is accompanied by low-grade inflammation [8] and activation of adipose 
tissue macrophages [9,10]. Another serious health condition connected to obesity is metabolic 
syndrome. It includes a group of risk factors for metabolic diseases, e.g. large waistline, high 
triacylglycerol level, low high-density lipoprotein cholesterol level, high blood pressure and 
high fasting blood glucose. Due to the rise of obesity, the metabolic syndrome is becoming 
a problem in nowadays society [11].  
 
1.1.2. Adipose tissue 
 
Adipose tissue (AT) has been increasingly recognized as a major player in systemic 
metabolic regulation [4] because it has a fundamental role in energy balance and overall body 
homeostasis [12]. Adipose tissue stores energy in form of lipid when energy intake exceeds 
expenditure [13] and then it can be utilized by the organism to fulfil subsequent metabolic 
requirements during times of little or no consumption [12]. It also acts as an endocrine organ 
and produces numerous bioactive factors which communicate with other organs and modulate 
a range of metabolic pathways (e.g. adipokines) [4]. Further, AT together with liver form 
a functional metabolic unit that is important for thermoregulation under the cold 
exposure [14]. Conversely, adipose tissue dysfunction plays a prominent role in the 
development of obesity and is related to disorders such as insulin resistance, cardiovascular 
diseases, diabetes, depression and cancer. Therefore, understanding its biology and pathology 
is of great importance for the identification of novel and potential therapeutic targets in order 
to prevent and treat of obesity-related disorders [4]. 
Adipose tissue is extremely plastic organ [7] which is distributed similar in mice and 
men [15] in various anatomical locations around body (Figure 2). Accumulation of visceral 
white adipose tissue (WAT) is in correlation with metabolic syndrome [7] whereas 
subcutaneous WAT is protective in the development of obesity and related metabolic diseases 
in rodents [16,17]. Also, it has been shown that subcutaneous fat improves glucose tolerance 
and insulin sensitivity in rodents. Unfortunately, metabolic function of subcutaneous and 
visceral fat in humans is still not clear today but it seems that fat distribution, rather than total 
fat mass, most likely plays an important role in the development of obesity and its associated 
diseases [4]. 
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Figure 2. Adipose tissue functions in energy homeostasis and thermal regulation. (A) In humans, BAT localized around the shoulders and 
ribs contributes to heat generation. Brown adipocytes exhibit abundant mitochondria and UCP-1 expression related to thermogenesis. It has 
been speculated recently that BAT efficiency for fat-burning could be harnessed to reduce obesity. Visceral WAT (VAT) and subcutaneous 
WAT (SAT) possesses considerable capacities for energy storage. VAT surrounds intra-abdominal organs, whereas SAT spreads throughout 
the body beneath the skin. These fat tissues secrete various adipokines to regulate energy homeostasis. VAT is more strongly associated with 
obesity-induced metabolic disorders than SAT. (B) In adult mice, BAT is well developed and easily observed compared with that in adult 
humans. Among WAT depots within the abdominal cavity, the paired gonadal depots located around the ovaries in females and the  testes in 
males are studied as a model of VAT. However, these depots do not exist in humans. The paired inguinal depots in the anterior to the upper 
part of the hind limbs are representative SATs in mice. Adapted from [18]. 
 
Adipocytes are the predominant cell type in adipose tissue [4] while the remainder are 
called stromal vascular fraction (SVF). SVF includes blood and endothelial cells, adipose 
precursor cells of varying degrees of differentiation, adipose-derived stem/stromal cells, 
smooth muscle cells, lymphocytes, pericytes, and fibroblasts [3,19]. Adipose precursors 
differentiate in three types of adipocytes, i.e. white, brown and beige (for details see below). 
They can coexist in one depot and their phenotype can be reversed. Interestingly, number of 
adipocyte is set in childhood and adolescence and it is independent on body weight 
fluctuation [7]. 
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White adipocytes are mainly present in white adipose tissue [20]. They have 
a unilocular lipid droplet, few mitochondria, low oxidative rate [21] and do not have 
uncoupling protein1 (UCP1) [7]. UCP1 is an unique protein that disconnects oxidative 
phosphorylation from ATP [22]. In line with this, white adipocytes have high capacity of 
storing energy in the form of triacylglycerols, and protect organs such as muscle and liver 
from lipotoxicity [4] that is associated with metabolic syndrome and T2D [23,24]. It has been 
known for several years that there is another type of WAT called beige or brite              
(brown-like-in-white) fat, in which UCP1 expression can be stimulated by cold stress or      
β3-adrenoceptor agonists [25]. Beige adipocytes that are predominant in beige fat can be also 
derived from white adipocytes in a process known as browning or beiging of WAT [26]. 
Conversely, brown adipocytes, located in brown adipose tissue (BAT), are specialized cells 
with multilocular morphology, abundant mitochondria and enrichment of UCP1 [4]. Typical 
depots of BAT are in Figure 2. Both brown and beige adipocytes generate heat on demand 
through UCP1-dependent uncoupling [14] and offer a new way to battle obesity and other 
metabolic disorders [26–30]. 
 
1.1.2.1. Metabolism of adipose tissue 
Adipose tissue, as an energy storage organ, stores triacylglycerols (TG) and releases 
fatty acids through lipogenesis and lipolysis, respectively [4]. Systemically, feeding stimulates 
the lipogenic pathway where excess of carbohydrate is converted into fatty acids in process 
de novo fatty acid synthesis (DNL). Then fatty acids are esterified to storage TG in the 
process called triacylglycerols biosynthesis [4][31]. Lipogenesis is primary active in the 
liver [31] where it is more efficient [32] than in adipose tissue. Conversely, fasting induces 
the activation of lipolytic pathway that promotes the breakdown of TG and release of fatty 
acids from adipose tissue. The balance between lipogenesis and lipolysis is critical for 
maintaining systemic energy homeostasis and insulin sensitivity [4].  
De novo fatty acid synthesis specifically, glucose is converted into pyruvate in 
glycolytic pathway. Then pyruvate enters tricarboxylic acid cycle in mitochondria and citrate 
is produced by this pathway. Later, citrate is converted into acetyl-CoA, malonyl-CoA and 
finally palmitate that is further metabolised into various fatty acids (Figure 3). Therefore, the 
main product of DNL is palmitate but stearate and shorter fatty acids are also generated [31]. 
High DNL is observed in the presence of high fatty acid oxidation while it may be related to 
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refilling of triglyceride stores and/or futile cycling [14]. Deregulation of DNL is associated 
with obesity or metabolic syndrome [31] because cells fail to respond to the normal action of 
insulin [33]. Of note, the plasma glucose levels, as well as insulin levels [4] associated with 
glucose intake, can stimulate lipogenesis whereas polyunsaturated fatty acids (PUFA) 
decrease lipogenesis by suppressing gene expression in murine liver [31].  
  
 
Figure 3. De novo lipogenesis: Glucose, taken up by the glucose transporter, enters the glycolytic pathway and generates pyruvate. This 
pyruvate is converted into acetyl-CoA that feeds the tricarboxylic acid (TCA) cycle. The citrate produced exits the mitochondrion and is 
converted back into acetyl-CoA by the enzyme ATP-citrate lyase (ACLY). Acetyl-CoA carboxylase (ACACA) acts on this acetyl-CoA 
yielding malonyl-CoA which is then utilized as a substrate for the production of 16-carbon saturated palmitate by the main biosynthetic 
enzyme fatty acid synthase (FASN). Adapted from [31]. 
 
Triacylglycerol synthesis occurs in multiple tissues, e.g. in the liver where very            
low-density lipoproteins (VLDL) are formed or in adipose tissue, and it is summarized in 
Figure 4 [34]. Briefly, TG synthesis combines the products of glycolysis,                
i.e. glycerol-3-phosphate or dihydroxyacetone phosphate with acyl-CoAs [12] to synthetize 
lysophosphatidic acid (1-acylglycerol-3-phosphate). Lysophosphatidic acid is further 
esterified and converted into phosphatidic acid (1,2-diacylglycerol-3-phosphate) that is 
shunted into the synthesis of various phospholipids or into the synthesis of TG. Entry into TG 
synthesis involves the conversion of phosphatidic acid to the intermediate 1,2-diacylglycerol 
(1,2-DG) that is subsequently converted to TG [34]. Diacylglycerol acyltransferase (DGAT) 
catalyses the final and critical step in the TG synthesis pathway, and plays an important role 
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in lipid deposition in adipocytes [35]. Of note, the storage of neutral TG in adipocytes 
increases the lipid droplet size, which results in adipose expansion and subsequent obesity [4] 
but on the other hand it avoids lipotoxicity [23].  
Opposite to lipogenesis, lipolysis is the catabolic process [4] leading to hydrolysis of 
the primary and secondary ester bonds between long chain fatty acids (FA) and the glycerol 
backbone in TG [23,36]. As a result, WAT releases free fatty acids and glycerol 
(Figure 4) [23,36] that can be transported in blood and subsequently taken up into muscles, 
liver and other organs while it drives lipid distribution and modulates the whole-body energy 
balance [4]. WAT-derived FA can be used as energy substrates (specifically for β oxidation 
and ATP production [24]), for generation of acylcarnitines and VLDL in liver [14,37], as well 
as an essential precursors for lipid and membrane synthesis and mediators in cell signalling 
processes [24]. Also, part of liberated FA can be re-esterified back to TG by DGAT1 and 
DGAT2 enzymes while it results in futile TG/FA cycling which is important biochemical 
activity in white adipocytes [7]. Lipolysis takes place in every organ but the most abundant is 
in white and brown adipose tissue [24]. The activation of the pathway is triggered by energy 
demand (e.g. exercise, fasting, cold exposure) [7,24], sympathetic tone and  β adrenergic 
signalling [14], or when the storage of neutral TG exceeds the capacity of adipocytes [4]. 
Lipolysis is catalysed by adipocyte triglyceride lipase (ATGL), hormone-sensitive 
lipase (HSL) or monoacylglycerol lipase (MGL) [12] and several hormones have been proved 
to regulate the lipolytic pathway as well, e.g. insulin, glucagon, catecholamine [4].  
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Figure 4. The enzymes of triacylglycerol synthesis and hydrolysis AGPAT: 1-acylglycerol-3 phosphate acyltransferase; ATGL: Adipose 
triglyceride lipase; CoA: Coenzyme A; DGAT: Diacylglycerol acyltransferase; DHAP: Dihydroxyacetonephosphate; DHAPAT: Acyl-
CoA:dihydroxyacetone-phosphate acyltransferase; DHAP-OR: Dihydroxyacetone-phosphate oxido reductase; FA: Fatty acid; GPAT: 
Glycerol-3-phosphate acyltransferase; HSL: Hormone-sensitive lipase; MGL: Monoglyceride lipase; PAP: Phosphatidic acid phosphatase; 
TAG: Triacylglycerol. Adapted from [34]. 
 
Unique immune cell repertoire in WAT suggests that the immune cells are involved in 
the control of mature adipocyte metabolism. Specifically, adipose tissue macrophages (ATM) 
contribute to low-grade adipose tissue inflammation and insulin resistance in obesity. 
Negative effect of excess lipids on macrophages could be partially ameliorated by          
omega-3 PUFA because they promote the ―healthy adipocyte‖ phenotype in mice and humans 
in epididymal but not subcutaneous WAT. ―Healthy white adipocytes‖ are characterized by 
high mitochondrial content, high lipolytic activity, especially high activity of TG/FA cycling, 
de novo lipogenesis and oxidative phosphorylation while they do not contain UCP1 
protein [7]. Interestingly, it may explain why 10-40 % of obese men stay metabolically 
healthy [38]. ATM as well as omega-3 PUFA are more discussed below.  
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1.1.2.2. Adipose tissue macrophages 
Adipose tissue macrophages are the predominant immune cell population in the adipose 
tissue, especially under obese conditions [39]. They play an essential role in immune response 
and normal tissue development [1,40]. Also, adipose tissue macrophages are associated with 
changes in metabolic state of the adipose tissue [41–43] and contribute to low-grade WAT 
inflammation and insulin resistance [44–46]. Further, they probably buffer the local acute 
increase in fatty acid concentration in plasma [10] because they internalize them [1,47] and it 
leads to formation of macrophages ―foam cells‖ [10]. Interestingly, ATM are the strongest 
predictors of T2D development in obese patients [48] and therefore there is a great effort to 
understand the role of ATM in metabolism at present days [1].  
Macrophages express a different functional program to adapt the microenviromental 
challenges as they are polarized from M1 to M2 state [49]. Polarization of macrophages is 
well defined in in vitro studies but it is more dynamic in vivo [10,50], it is influenced by 
dietary lipid composition for example [10,50,51]. Specifically, omega-3 PUFA support switch 
from M1 to M2 phenotype via anti-inflammatory lipid mediators derived from                 
omega-3 PUFA [8,49,52]. Obese individuals have more M1 macrophages [1]. They originate 
from monocytes and secrete high levels of proinflammatory cytokines [1] (e.g. IL6,          
TNF-α [40] and IL-1β, which can inhibit insulin signalling [39]). Also, M1 lead to the 
development of type 2 diabetes [1] and contribute to the formation of ‗crown-like structures‘ 
that surround dying adipocytes [39]. On the other hand, M1 protect the host against different 
types of microbial threats [53]. Conversely, alternatively activated macrophages, called M2, 
are anti-inflammatory and they are predominant in lean individuals [1]. M2 are activated by 
IL-4 [40] and express the anti-inflammatory cytokine IL-10 [39]. Moreover, M2 contribute to 
a metabolic homeostasis in the lean adipose tissue [39], promote WAT remodelling and 
support systemic insulin sensitivity [52,54,55].  
 
1.1.3. Metabolome 
 
Metabolome is the global collection of all low molecular-weight metabolites that are 
produced by cells during metabolism, and provides a direct functional readout of cellular 
activity and physiological status [56]. In general, metabolites can be polar (e.g. acylcarnitines 
and amino acids) or nonpolar (e.g. lipids). Lipids as well as acylcarnitines and amino acids are 
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more discussed below. Central carbon metabolism is a major pathway from which the 
metabolic fluxes are distributed to different branches and it builds-up the storage pool when 
nutrients are in excess and balances the biosynthesis precursors and energy supplies as well. 
Although metabolic pathways are known for decades the regulation and quantification of 
metabolic network is not fully understood [57]. It is crucial to be able to determine and 
quantify metabolites to understand the metabolic response in health and disease state [58,59]. 
Simultaneously analysing of hundreds of endogenous metabolites presents a challenge 
because of their chemical diversity, different chemical structures and properties [60]. Also, 
metabolites can be present in trace levels in cellular and intracellular compartments and thus 
we need very sensitive technique to recover and detect as many metabolites as possible [61]. 
Mass spectrometer seems as an optimal platform for target metabolomics [60].  
 
1.1.3.1. Acylcarnitines and amino acids 
Acylcarnitines (AC) and amino acids (AmA) are associated with obesity and adipose 
tissue metabolism. Specifically, it has been shown that both AmA and AC have influence on 
development of insulin resistance [62] and impaired glucose tolerance in diabetes [63].   
Acylcarnitines are the intermediates of fatty acid and amino acid oxidation [63], they 
are involved in energy metabolism and adenosine triphosphate production [11] and they are 
important diagnostic markers as well [63]. Specifically, their measurement in plasma is a 
useful tool for early diagnosis of inherited disorders of fatty acids catabolism [64] and        
odd-numbered AC are newly discovered as potential markers of the metabolic   
syndrome [65–67]. Unfortunately, the cause of changes in AC levels in disease [63] or during 
development of obesity state [68] is still unclear. Amino acids play central role as substrates 
in organ metabolism [69]. Complete oxidation of amino acid´s carbons occurs only if their 
carbons are ultimately converted to acetyl-CoA and then acetyl-CoA is oxidized to CO2 and 
H2O via the Krebs cycle and mitochondrial electron transport system [70].  
In general, higher rate of fatty acid oxidation and augmented levels of long-chain AC 
were discovered in plasma during fasting [71]. Also, it has been shown that increased levels 
of AC with long chain can be found in serum during obesity [68]. Conversely, insulin reduces 
all plasma AC species in humans [66]. Acylcarnitines specifically, AC with long chain and 
C4-OH are linked to obesity and T2D in humans [68], metabolite C3:0, C5:0 and C4DC were 
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reported as biomarkers of T2D [63,65] and acylcarnitine C16-DC is related to peroxisomal 
fatty acid oxidation [68]. Furthermore, higher plasma levels of amino acid ornithine were 
found in obese mice [72].  
 
1.1.3.2. Lipids 
Cellular lipids are the major constituents of animal and plant cells and main 
components of lipoproteins in serum. Most of them are not soluble in water but only in      
non-polar solvents [73]. Lipids are composed from defined building blocks [74]. Usually they 
consist of polar hydrophilic head group and non-polar hydrophobic part 
(i.e. glycerophospholipids) but some lipids are composed of non-polar components only 
(i.e. triacylglycerols, diacylglycerols, cholesterolesters). The polar head group of lipids 
defines the individual lipid class [73]. Lipid classification into 8 classes is recommended by 
LIPID maps consortium and the classes are fatty acids, glycerolipids, glycerophospholipids, 
sphingolipids, sterol lipids, prenol lipids, saccharolipids and polyketides [74,75]. The most 
abundant lipid classes are triacylglycerols (TG) and phospholipids [76–78]. Triacylglycerols 
serve as important energy storage depots, risk predictors for cardiac diseases or 
diabetes [79,80] and they are main components of adipose tissue [81]. Further, fatty acids may 
be saturated, monounsaturated or polyunsaturated while predominant fatty acids contain 16 
and 18 carbons in chain [81]. Interestingly, new lipid classes are still being discerned by target 
biochemical approaches [74].  
Lipids have many function in organism [82–84]. Firstly, lipids are part of membranes 
as they create the hydrophobic barriers and separate cellular compartments in biological 
organism. Secondly, they are optimal matrix to facilitate specific conformations, interactions 
and dynamics for the activity of transmembrane proteins. Also, lipids are perfect energy 
reservoir (e.g. triacylglycerols) and storage depots of bioactive second messenger 
(e.g. eicosanoids, diacylglycerols). Messenger can propagate cellular signalling for cell 
growth, differentiation, death and response to stimuli [73]. Of note, lipid metabolism is crucial 
for energy homeostasis [81]. Levels of lipids are strictly regulated and misbalance in their 
levels or in lipid metabolism may lead to rise of pathologies [81], e.g. tumour 
development [11]. Lipid´s transportation in blood circulation has two main channels, one is 
for lipids that come from diet and second carry out lipids originated from liver [81]. Besides 
these two channels there is also reversed transportation of cholesterol [85]. 
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Lipidomics aims to study the pathways and networks of the cellular lipids by 
characterization and quantification of all lipids presented in biological system [73,86]. It is 
a part of metabolomics [81] and was emerged in 2003 [11]. Lipidomics has two directions: 
target and global analysis. Target analysis of lipids focuses on known lipids and develops 
a specific method with a high sensitivity for quantitative analysis of these lipids. Thus, target 
analysis is commonly used for studying signal processing. Contrarily global analysis is 
an untargeted analysis that aims at detecting every lipid species presented in the sample. 
Therefore global analysis is useful for studying lipid metabolism, molecular mechanisms and 
biomarker´s discovery [11]. Determination of lipids is challenging because they have totally 
different polarity states [74,87] and cellular lipidome is dynamically changing at any moment 
by nutritional status, health conditions, etc. [73]. Lipidomics utilizes mainly principles and 
technological tools of analytical chemistry, particularly mass spectrometry [11]. 
Establishment of a powerful method for lipidomic analysis is very important [73] because it 
can show problems in lipid metabolism including risk factors for many diseases, e.g. cancer, 
atherosclerosis, diabetes [88–90]. Moreover, lipid biomarkers help to elucidate the 
inflammatory processes through determination of eicosanoids, leukotriens etc. [91]. 
Nevertheless, there are a few areas of technological progress that need further development. 
First, it is still impossible to determine a whole cellular lipidome. Then bioinformatics for 
interpreting large sets of data is limited, and finally, a definitive unravelling of the 
biochemical mechanisms responsible for a disease state is still rare [11].  
 
Omega-3 polyunsaturated fatty acids  
Omega-3 PUFA belong to the lipid family of polyunsaturated fatty acids (PUFA). 
Number 3 in the term defines the position of the double bond that is closest to the methyl 
terminus of fatty acid´s acyl chain, i.e. all omega-3 PUFA have double bond on carbon 3 [92]. 
PUFA are key components of the phospholipids in cell membranes [92] and they are 
precursors of many metabolites [93]. Alpha-linolenic acid (18:3, known as ALA), 
eicosapentaenoic acid (20:5, known as EPA) and docosahexaenoic acid (22:6, known as 
DHA) are common omega-3 fatty acids found within biological membranes [94]. Indeed, 
ALA is the major omega-3 PUFA contained in most of human´s diets because it is in plants, 
nuts, seed etc. [92]. Animals and humans cannot synthetize ALA unlike plants [92] but 
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animals can metabolize ALA to eicosatetraenoic acid (20:4, omega-3 PUFA) and further to 
EPA and DHA [81,95].  
Marine omega-3 PUFA have anti-inflammatory properties [96–98], exert beneficial 
metabolic effect and counteract adverse effects of obesity [99]. Its positive impact on obesity 
is explained by amelioration of low-grade inflammation in WAT, liver, as well as in other 
tissues while it results in the preservation of the ―healthy adipocyte‖ phenotype in WAT (for 
details see above). Although it was shown that omega-3 PUFA could decrease the size of fat 
cells in humans with diabetes weight reduction was observed only for mice not for 
humans [7]. We have demonstrated in our clinical trial that omega-3 PUFA could improve 
postprandial lipid metabolism in overweight/obese patients with type 2 diabetes but they 
cannot reverse type 2 diabetes [100]. Nevertheless omega-3 PUFA are invaluable in 
stimulating the synthesis of anti-inflammatory lipid mediators in obese WAT (the lipid 
mediators are discussed below) [99]. Further, omega-3 PUFA could partially improve the 
negative effect of excess lipids on macrophages and increase the rate of FA re-esterification 
and oxidation [49]. Several studies have also shown that they reduce circulating levels of 
triacylglycerol in both obese mice and humans but on the other hand they enhance insulin 
sensitivity only in obese rodents and not in humans [7]. Omega-3 PUFA are protective against 
coronary heart disease [7] and ischaemic stroke as well [101]. Of note, the impact of      
omega-3 PUFA can be augmented by combined intervention, e.g. caloric restriction, 
exercising in humans or administration of anti-diabetic drugs [7]. 
Omega-3 PUFA are present in marine fish while the seafood is a good source of them 
as well [92]. World health organisation recommends regular fish consumption (1-2 servings 
per week) while serving should provide an equivalent of 200-500 mg of eicosapentaenoic and 
docosahexaenoic acid [89]. A single lean fish meal (e.g. cod) could provide about 0.2 to 0.3 g 
of marine omega-3 PUFA. On the other hand single oily fish meal (e.g. salmon or mackerel) 
could provide as many as 1.5 to 3.0 g of these fatty acids. It seems that a dose of at least 2 g 
per day is necessary to achieve omega-3 PUFA´s anti-inflammatory effect while this would 
equate to about 30 mg per kg body weight and day. It means one meal of salmon or mackerel 
every day which is almost impossible. The most effective strategy is to add fish oil 
concentrate (not only fish oil capsule which is also insufficient) as a nutritional 
supplement [92]. Interestingly, metabolic efficacy and bioavailability of omega-3 PUFA 
depend on their chemical binding form [50], e.g. omega-3 PUFA in a form of phospholipids 
are better than in a form of triacylglycerols [102].  
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Lipid mediators 
 
Figure 5. Overview of lipid mediators in WAT. Production of lipid mediators begins on the plasma membrane, where phospholipids (violet) 
are cleaved by phospholipase A2 to yield free arachidonic (AA) , eicosapentaenoic (EPA) or docosahexaenoic (DHA) acids, which  are 
subsequently metabolized into either eicosanoids (orange, yellow, green) or docosanoids (blue) by a variety of enzymes. Endocannabinoids 
(red) come either from membrane phospholipids via N-acyl-phosphatidylethanolamine intermediate or from 1,2-diacylglycerol, product of 
PIP2, PA or TAG metabolism, in case of 2-AG. 2-AG, 2-arachidonoyl glycerol; AA, arachidonic acid; AEA, arachidonoylethanolamide; 
ATGL, adipose triglyceride lipase; COX, cyclooxygenase; DAG, diacylglycerol; DAGK, diacylglycerol kinase; DGL, diacylglycerol  lipase; 
DHEA, docosahexaenoylethanolamide; − EA, − ethanolamide; EPEA, eicosapentaenoylethanolamide; FAAH, fatty acid amide hydrolase; 
HSL, hormone-sensitive lipase; HX*, hepoxilin; LOX, lipoxygenase; LT*, leukotriene; MGL, monoacylglycerol lipase; n.e., non-enzymatic 
oxidation; NAPE-PLD, N-acyl phosphatidylethanolamine-specific phospholipase D; NAT, N-acyl transferase; OEA, oleoylethanolamide; 
P450, cytochrome P450; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEA, palmitoylethanolamide; 
PG*, prostaglandin; PIP2, phosphatidylinositol biphosphate; PLC, phospholipase C; TX*, thromboxane. For nomenclature of lipid 
mediators see LIPIDMAPS.org. Adapted from [50]. 
 
Oxidation of polyunsaturated fatty acids leads to production of lipid mediators through 
enzymatic, i.e. cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP) 
reactions, or free radical-mediated reactions. Lipid mediators occurred in WAT are shown in 
Figure 5. They are involved in many biochemical and signalling pathways, especially in 
inflammatory environment [93]. High storage capacity of WAT for omega-3 PUFA indicates 
that this tissue is very important as a source of various types of omega-3 PUFA-derived lipid 
mediators [7]. Interestingly, new families of these lipid mediators have been discovered in last 
10 years [92], e.g. FAHFA (for details see below). Lipid mediators derived from arachidonic 
acid (20:4, omega-6 PUFA, known as AA) are predominantly proinflammatory whereas EPA 
(20:5, omega-3 PUFA) derived mediators have opposite effect [93]. Also, it has been reported 
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that lipid mediator protectin D1, analyte of our interest, decreases accumulation of adipose 
tissue macrophages, shifts polarization of macrophages towards M2 and improves insulin 
sensitivity in obese mice [103–105].  
Eicosanoids are lipid mediators derived from 20-carbon PUFA, especially arachidonic 
acid [92] or eicosapentaenoic acid [93]. They are key mediators and regulators of 
inflammation [106–108] and their precursors (corresponding fatty acids) are released from the 
membrane phospholipids due to inflammatory stimuli. Of note, EPA-derived eicosanoids are 
usually less biologically active than AA-derived [92]. Endocannabinoids are complex 
eicosanoids that are produced by cleavage of phospholipids by phospholipases [109]. They 
regulate food intake, energy balance as well as lipid and glucose metabolism and 
inflammation [110]. The two major endocannabinoids, anandamide (AEA) and                        
2-arachidonoylglycerol (2-AG), have pro-inflammatory properties and they are associated 
with obesity. Omega-3 PUFA reduce the level of arachidonic acid in membrane phospholipids 
and thus suppress the amount of endocannabinoids in peripheral tissues [8]. Specifically, 
administration of omega-3 PUFA leads to sustained decreased levels of 2-AG and AEA in 
WAT of obese mice. In contrast, the amount of 2-AG and AEA in patients with T2D remains 
unchanged despite omega-3 PUFA supplementation [7].  
Branched fatty acid hydroxy fatty acids (FAHFA) are newly discovered lipid 
molecules first described in 2014 by Yore et al. [111]. They are members of a lipid class 
called estolides (intermolecular esters of hydroxy fatty acids), i.e. wax [112]. FAHFA are 
synthetized by adipose tissue [113] and they were detected in both human and mice 
WAT [99]. In general, they could improve local and whole body glucose metabolism [3]. 
Also, FAHFA decrease accumulation of macrophages, expression of pro-inflammatory 
adipokines and promote macrophages polarization toward M2 metabotype [7]. We were 
focused on novel member of this family, i.e. omega-3 PUFA docosahexaenoic acid esterified 
to 9- and 13-hydroxyoctadecadienoic acid (HLA) that is termed 9-DHAHLA and                 
13-DHAHLA. 
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1.2. ANALYTICAL CHEMISTRY 
 
We utilized particularly very sensitive liquid chromatography and mass spectrometry 
detection to study adipose tissue metabolism. Here, we discuss preparation of samples, then 
we describe analytical techniques used in our research and finally we devote to quantitative 
analysis. 
 
1.2.1. Preparation of metabolomic and lipid samples 
 
1.2.1.1. Metabolomic samples 
First, cell metabolism must be interrupted by quenching to obtain metabolomic 
samples. Quenching is a drastic change of temperature or pH and is necessary because levels 
of metabolites can be changed in any moment [81]. Then samples are separated from biomass 
by adding an organic solvent/solvent mixture, e.g. acetonitrile [81] or methanol [114]. Thus 
the high-molecular-weight species (i.e. proteins and RNA) precipitate and they can be 
removed by centrifugation step and we acquired metabolite-containing supernatant for 
analysis [114]. Lastly, the solvents are evaporated and samples are concentrated [81] while 
the sample solutions can be reconstituted in a high aqueous solvent for reversed-phase 
applications or high organic solvent for direct analysis without lyophilization in HILIC 
applications. Of note, internal standards can be spiked into samples for quantitative analyses 
where they compensate variability in sample processing and analytical platform 
operation [114]. 
 
1.2.1.2. Lipid samples 
Lipid extraction process exploits the high solubility of lipids in organic solvent [11]. 
Unfortunately, it is impossible to have one extraction method for all lipid species because 
lipids are very divergent [86]. In general, lipid extraction helps to remove salts and protein 
that interfere with separation techniques or mass spectrometry detection from sample [86] and 
simultaneously preserves lipids for further analyses [11]. The two lipid extraction processes 
are liquid/liquid or solid phase extraction (for details see below). 
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In practice, lipids in tissue and cells are relatively protected by natural antioxidant 
system but they can be more prone to chemical and enzymatic modification due to sample 
homogenization. To avoid these modifications it is recommended to work at temperature 
close to 0 °C and to add a small percentage of organic solvent or the antioxidants 
(e.g. butylated hydroxytoluene [115]) to the homogenization buffer. Also, the extracts should 
be stored in glass vials, solubilized in sufficient organic solvent at -80 °C and inert gas should 
be kept in vials instead of air/oxygen [86]. Polyunsaturated lipids are susceptible to 
photodegradation and it is better not to work with them in direct sunlight [93].  
 
Liquid/liquid extraction (LLE) 
Liquid/liquid extraction (LLE) is based on the partition of an analyte between two 
immiscible (organic/aqueous) phases and it is used to extract groups or families of 
molecules [116]. Usually, lipids portion into the organic phase, water soluble molecules 
remain in the aqueous phase and protein are precipitated [86]. The solvent choice is based on 
its polarity; generally, polar solvents extract polar analytes more efficiently than the apolar 
analytes. The advantage of using this method is that it is both inexpensive and easy to 
implement. Contrarily, it has the inconvenience of being time-consuming, difficult to 
automate, often consuming toxic solvents and less efficient for highly polar compounds [116].  
Two well established LLE platforms are methods by Folch [117] and 
Bligh&Dyer [118]. Bligh&Dyer extraction utilizes solution chloroform/methanol/water 
(1:1:0.9, v/v/v) and it is appropriate for a small amount of sample (less than 50 mg). 
Extraction solution for modified Folch method is chloroform/methanol (2:1, v/v) while water 
or 0.9% NaCl wash the solvent extract. This approach is convenient for sample size of 
100 mg [11]. Both platforms as well as their modifications are widely used today [86,115]. 
Nevertheless they have same drawbacks, e.g. working with hazardous chloroform and quite 
a demanding collection of chloroform phase with lipids [11].  
Other extraction approaches used in lipidomics are methyl-tert-butyl ether (MTBE) 
and butanol/methanol (BUME) methods. Extraction solution of MTBE approach is       
methyl-tert-butyl ether/methanol/water (5:1.5:1.45, v/v/v/v). Methyl-tert-butyl ether presented 
in the top layer [11] has lower density than water [86] and therefore it is more suitable to 
remove this phase after phase separation [11]. The limitation of this approach is that MTBE 
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phase with lipids may also contains aqueous component which may carry over the           
water-soluble contaminants. Finally BUME method, butanol/methanol (BUME, 3:1, v/v) are 
added to a small volume of aqueous phase and then equal volume of heptane/ethyl acetate 
(3:1, v/v) and 1% acetic acid are added there as well. This approach ensures that less       
water-soluble contaminants are carried over in organic phase but on the other hand it is 
difficult to evaporate the butanol in organic phase [11].  
 
Solid phase extraction (SPE) 
Solid phase extraction is a sample preparation technology that uses solid particle, 
i.e. chromatographic bed, to chemically separate different components of a sample [119]. The 
approach is based on the partition of a sample between a mobile liquid phase (the biological 
matrix and various solvents) and a solid stationary phase [116] while sample is nearly always 
in the liquid state [119]. It uses the same basic chromatographic principles as high 
performance liquid chromatography, but in a different format and for a different reason. Here, 
chromatography is used to better prepare a sample before it is submitted for analytical 
testing [119]. Since its introduction, many stationary phases have been developed, allowing 
more targeted extractions or adaptations for the extraction of a large number of chemicals of 
various types. The diversity of stationary phases allows extraction of polar compounds that 
were previously difficult to extract by organic phases [116]. Today, scientists find SPE very 
useful in solving difficult sample preparation and analytical problems [119], for example to 
characterize a specific compound or a family of compounds [116] and for the selective 
removal of interferences from sample [119]. 
There are many benefits of using SPE. First, it can reduce ion suppression in mass 
spectrometry applications and enables us to detect trace concentration of very low level 
compounds. Then SPE can simplify complex sample matrix along with compound 
purification and fractionate sample matrix. For example, different classes of compounds 
separated by their polarity are in Figure 6 while then they are separately analyzed in a much 
more efficient way because their compounds would be more similar [119]. 
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Figure 6. Sample preparation by SPE. Adapted from [119]. 
 
We utilized offline solid phase extraction procedure, which can be performed on SPE 
cartridges or 96 well plates, and consists of four main steps. First step is the conditioning of 
the stationary phase that regenerates retention sites involved in the molecular 
interactions [116]. Subsequently, the sample is loaded on the cartridge [93,116]. The  flow 
rate during sample loading has to be appropriate because too fast a flow rate may lead to 
reducing the efficiency at which analytes are retained on cartridges [93]. Also, acidification of 
sample before the extraction helps to protonate lipid mediators and allows them to be retained 
on a cartridge [92]. Later on, SPE column is washed while it aims to eliminate               
weakly-retained molecules [116] or remove excess salts and another water-soluble 
impurities [92]. Then cartridges are washed by hexane to remove any water in lipid extraction 
processes [92]. Finally an appropriate organic solvent, e.g. methylformate for lipid 
mediators [92], is used to elute the analytes [116]. These extracts are dried in Speedvac or 
using SPE drying attachment with nitrogen supply and reconstituted in the mobile phase used 
in the mass spectrometry (MS) measurement. Wash volumes, used in SPE, are determined by 
the mass of the sorbent bed, commonly it is 1 ml of solvent per 100 mg of bed mass. 
Nevertheless usually larger volumes are utilized for lipid extraction in order to remove all 
weakly bound impurities from sorbent bed, e.g. 4x5 ml on 500 mg sorbent bed. It is important 
because impurities can cause ion suppression on MS and loosing MS sensitivity. Of note, 
extracts from solid tissue samples larger than 200 mg may potentially cause ion-suppression 
in mass spectrometry and contaminate the system as well [92].  
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1.2.2. Liquid chromatography 
 
1.2.2.1. In general 
High performance liquid chromatography (HPLC) utilizes either a solid or           
liquid-coated solid stationary phase and a liquid mobile phase to separate the analytes through 
adsorption of analyte to the stationary phase [120]. This technique is able to discover and 
quantify low or trace-abundance lipid species and allows separation of complex 
mixtures [121]. Also, HPLC offers the most flexibility for interfacing with various detection 
systems, e.g. mass spectrometry [115]. In general, liquid chromatography is very sensitive, 
robust [59] and has resolution and speciﬁcity [120].  
Liquid chromatographic separation coupled to mass spectrometry (LC-MS) can 
simplify complex sample extracts [121] and analyse large nonvolatile polar compounds 
without derivatization [122]. LC-MS is appropriate for analysis of lipid extracts [121] or for 
distinguishing of isomeric species with the same mass (i.e. isobaric compounds) [93,115]. 
Also, it is popular tool for identification of metabolites [68] because it can reduce high 
complexities of biological samples [11]. Main advantage of LC-MS is its compatibility with 
commonly used solvents [122] and the option to choose different columns for separation [60]. 
HPLC with MS detection is fast additionally and sample preparation for that analyses is 
simple [60]. On the other hand, LC-MS can make high abundance lipids more concentrated 
and it leads to forming the aggregates and decreased ionization efficiency [121]. Moreover, 
only limited number of retention times can be observed in chromatogram in one run. LC-MS 
data include both mass spectra and chromatogram with retention time that also helps to 
identify the analytes [11]. Unfortunately, mass spectral libraries are not currently available 
because of non-reproducibility between different LC-MS systems caused by differences in 
liquid chromatography column chemistries and mass spectrometer designs [114]. 
Ultra performance liquid chromatography (UPLC) is category of HPLC that utilizes 
column particles smaller than 2 µm in diameter. These particles create very high operating 
pressures (in the range of 6000 to 15,000 psi) and it results in superior resolution, speed, and 
sensitivity compared with HPLC [123]. Also, UPLC substantially increases a number of 
detected metabolites when compared with traditional HPLC. In general, ultra performance 
liquid chromatography coupled to mass spectrometry provides high mass accuracy and its 
linear dynamic range can operate over three to five orders of magnitude [114].  
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1.2.2.2. Liquid chromatography modes 
Most lipidomic applications use reversed-phase column chemistries although other 
chemistries, e.g. hydrophilic interaction chromatography or normal phase chromatography, 
are also utilized [114]. Typical mobile phase for lipidomic analysis is a mixture of aqueous 
buffer with methanol or acetonitrile but hexane or isopropanol are also used as 
cosolvents [115]. Metabolites can be determined by ion-pair, hydrophilic interaction liquid 
chromatography, ion exchange, normal phase [59] or reverse phase chromatography coupled 
to triple quadrupole or ion trap [87]. 
 
Reversed phase chromatography 
Reversed phase (RP) chromatography has a nonpolar capped silica stationary phase 
and polar mobile phase [115] and it allows separation of individual lipid species due to their 
different hydrophobicities [121]. Usually, RP starts with a high aqueous content mobile phase 
(with modifiers, e.g., formic acid) and the organic phase fraction is increased, typically 
operating from 100% aqueous to 100% organic. The organic solvent is commonly either 
methanol or acetonitrile. Acetonitrile is a more non-polar (or lipophilic and hence ‗stronger‘) 
organic solvent and operates at lower back-pressures, although it can present problems with 
elevated background and reduced sensitivity at high acetonitrile concentrations [114]. Salts 
(e.g. ammonium acetate, ammonium formate or acetic and formic acid [115]) in mobile phase 
help to retain polar compounds on RP column but their high concentration can cause the 
signal instability, ion suppression or contamination of MS source [122,124]. Therefore 
application of pH in mobile phase instead of salt gradient may allow mass spectrometry 
detection [125]. 
In practice, the same gradient elution program utilized in both positive and negative 
mode offers advantages in metabolite identification because single metabolite is recorded with 
the same retention time in both ion modes. The use of reversed-phase chemistries provides 
efficient retention and separation of relatively nonpolar metabolites across a large molecular 
weight range (50 to >1,500) and includes high-molecular-weight lipid species 
(e.g. phospholipids and triacylglycerols) and nonpolar amino acids (e.g., tryptophan) [114]. 
Also, hydrophobic molecules (lysophosphatidylcholine, lysophosphatidylethanolamine) are 
separated by reverse phase chromatography [125,126]. Oxygenated PUFA mediators are 
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usually separated on octadecyl (C18) reversed phase column with acidified methanol or 
acetonitrile-based mobile phase system due to their polarity [92]. Phospholipids with long 
fatty acyl chains are quite non-polar and thus highly organic solvents are needed to remove 
them from C18 column and more polar oxidized and chain-shortened forms of phospholipids 
elute at the beginning of analysis on butyl column with high aqueous content in mobile 
phase [115].  
 
Normal phase chromatography 
Normal phase (NP) chromatography involves a silica stationary phase with nonpolar 
mobile phase [115]. NP is able to separate complex lipid extract to individual lipid 
classes [121] and it is the most effective for separation of phospholipids [115]. Unfortunately 
the solvents are only partially soluble [127] and less well suited to generating a good 
electrospray of mass spectrometer [115].  
 
Hydrophilic interaction liquid chromatography 
Hydrophilic interaction liquid chromatography (HILIC) is a more robust form of 
a normal phase separation [115] and it utilizes a polar stationary phase in combination with 
a mobile phase, containing high concentration of organic solvent in water [128]. The primary 
function of HILIC stationary phase is to bind water at its surface (see Figure 7) [127]. The 
mechanism of separation is complicated. Although HILIC is traditionally assumed to result 
from the partition between the aqueous layer accumulated close to the solid surface and 
a highly organic bulk mobile phase the separation mechanism is obviously more complex. 
Differences in the chromatographic selectivity of various polar compounds indicate that 
adsorption on the polar centres on the solid phase surface may also contribute to the retention. 
Also, mixed retention mechanism (e.g. polar, hydrophobic or ion exchange interactions) 
potentially conduces to the retention of sample compounds. Specifically, polar interactions 
control the retention in acetonitrile-rich mobile phases, whereas the column may show 
essentially reversed-phase behaviour with the major role of hydrophobic interactions in highly 
aqueous mobile phase [128].  
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Properties of HILIC separation systems strongly depend both on the stationary phase 
and the composition of the mobile phase [128]. For example, high organic content in mobile 
phase leads to high ionization efficiency of HILIC [127,129]. Yet the technique is 
versatile [130] and enables faster separation compared to reverse phase chromatography 
because of lower viscosity of eluent [129]. Furthermore HILIC is well compatible with mass 
spectrometry [115,127] and it is advantageous that it can be used without ion pair 
reagent [131]. Of note, many new types of columns based on silica gel have appeared in the 
past years, e.g. organic polymers [128] or ZIC-HILIC [127]. ZIC-HILIC is a sulfoalylbetaine 
(zwitterionic) phase that incorporates a positive and negative charge in relatively long alkyl 
chain and thus it can undergo electrostatic interaction and attract polar molecules [127]. 
Hydrophilic interaction liquid chromatography provides an alternative approach to effective 
separation of polar analytes in compares to RP because these analytes elute very 
early [126,129] or they are not sufficiently retained [114,122,128] on conventional RP phases. 
Therefore HILIC is suitable for separation of strongly or moderately polar (hydrophilic) 
samples [126–128] and it also allows simultaneous separation of different classes of important 
metabolites [130].  
 
Figure 7. Graphical representation of the micro environment around the surface of the stationary phase in HILIC chromatography. Adapted 
from [132]. 
 
 
1.2.3. Mass spectrometry  
 
1.2.3.1. In general 
Mass spectrometry (MS) is a powerful analytical technology that can be used to 
identify unknown organic or inorganic compounds, determine the structure of complex 
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molecules, or quantitate extremely low concentrations of known analytes. Molecules must be 
ionized, or electrically charged to produce individual ions and must be present in the gas 
phase for MS-based analysis. MS instruments analyse molecules by relating the mass of each 
molecule to the charge; this identifying characteristic is specific to each molecule and is 
referred to as the mass-to-charge ratio (m/z). Ions produced from small molecule analytes 
(1000 Da) usually possess a single charge; therefore, their m/z is equivalent to the mass of the 
ion. This is commonly designated as [M+H]
+
 for protonated (positive) and [M−H]− for 
deprotonated (negative) ions. Relative ion abundance of a specific m/z is plotted versus time 
in chromatogram [133]. Mass spectrometer is able to fragment the ions and measure the m/z 
of product ion which together allow the identification of many compounds [115]. Also, 
multiple overlapping chromatograms can be extracted from the same analytical run, as the 
mass analysers are able to detect multiple ions independently within the time scale of 
a chromatographic peak [133]. 
Mass spectrometry measurement in practice, the sample is introduced into the ion 
source through a charged capillary or by direct infusion of the sample using a syringe pump 
(i.e. shotgun approach) or by coupling to a liquid chromatography system (i.e. LC-MS) [115]. 
Molecules are ionized in ion source and then directed [133] using electric field and mass 
filtres [86] to the mass analyser where individual ions are selected according to their 
m/z [133]. Of note, ion suppression is a negative effect that influences the ionization of 
analyte by the presence of other endogenous or exogenous molecules and must be 
avoided [86].  
The analytical power of the mass spectrometer lies in its resolution [133]. Mass 
resolution is the minimum mass difference between two mass spectral peak and therefore it is 
a measure of the ability to distinguish two peaks of different elemental composition [134]. 
The higher the value the better the resolution [86], but overly high resolution can be 
problematic as well because of potential overlaps analytes [11]. Next characteristic of MS is 
mass accuracy that is defined as the mass difference detected by the analyser divided by the 
observed, or true mass [133]. Resolving power refers to an instrument‘s ability to distinguish 
two adjacent ions of equal intensity [135] and it is a measure of precision over a wide range of 
m (or m/z) [134]. Moreover, resolving power is useful for evaluating mass analyser 
performance and may be defined either for a single peak of mass or for two equal-magnitude 
peaks [134]. Other properties of mass spectrometry is high sensitivity [81], specificity and 
coupling capability to separation technologies [60,136]. Sensitivity is the amount of moles 
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that can be detected by instrument (usually in fentomol range) [86] whereas selectivity of MS 
is achieved by identification of species coeluted during chromatography by their m/z [115]. 
Mass spectrometry is also high throughput approach [81] while typical dynamic range of 
standard MS instrument is 10
3
-10
4 
and more modern instruments using selective ion scanning 
methods have reached 10
5
 [115]. Collision energy is required for fragmentation of the 
individual lipid molecules and it needs to be experimentally established [92]. The dwell time 
is time taken collecting data at each step during scanning in first quadrupole in triple 
quadrupole analyser. Usually sufficient dwell time is 10-50 ms but longer dwell time gives 
better sensitivity (i.e. signal to noise) at a cost of either lower resolution on the mass spectrum 
or fewer data points per unit time which makes quantification from liquid chromatography 
less reliable [115].  
Utilizing the mass spectrometry is key in lipidomics [137–143]. Unfortunately, one 
single platform to fully characterize the lipids do not exist [86] and the best option is to 
combine several different techniques (e.g. MS imaging, LC-MS etc.) to yield the most 
complete lipidomic data set [144]. Due to lipid´s structural characteristics their identification 
from ion mass fragment spectra is generally easier to obtain than with other molecular 
compounds [81]. Limit of detection in MS lipidomics can be amol/mg protein of tissue or cell 
or amol/ml of body fluid [11]. In practice, most phospholipids are zwitterionic and their 
longer chain usually needs higher collision energy [115]. Wide range of lipids 
(e.g. phosphatidylcholines and phosphatidylethanolamines [115]) are analysed in a positive 
MS mode in which they form positive aducts [73,145], i.e. [M]
+ 
[115],  [M+H]
+
, [M+Na]
+
 or 
[M+NH4]
+ 
[145]. Especially sodium aducts highly occur because sodium is presented very 
often in natural sources and has high affinity to lipids (e.g. TG) [73]. Also, negative ionization 
provides superior results for certain lipid classes (e.g. phosphatidylinositol, 
phosphatidylserine, and phosphatidic acid [145]) as their phosphate group is deprotonized   
[M-H]
-
 [115]. Although fatty acyls are measured more often in negative mode because they 
are ionized more efficiently under these conditions [146] they can form protonated molecules 
[M+H]
+
 as well [87]. Of note, decay of molecules in fragmentation cell helps to get 
information about the distribution of fatty acyl chains and oxidation sites [115]. 
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1.2.3.2. Instrumentation 
 
Ion source 
Molecules of analytes have to be ionized by ion source before their detection in mass 
spectrometer. The most common ion sources in lipidomics are electrospray (ESI), 
atmospheric pressure chemical ionization (APCI) and matrix assisted laser 
desorption/ionization (MALDI). All three belong to soft techniques which means that very 
little fragmentation occurs during the ionization process and monocharged molecular ions are 
provided [86]. These ion sources are ―direct ionization sources,‖ in which analytes are directly 
ionized from a surface (i.e. MALDI) or from a solution (i.e. ESI) [133].  
First APCI, it works under atmospheric pressure and both solvent and analytes are in 
the gas phase [86]. Unfortunately, the technique is not soft enough [73] and it is often less 
susceptible to matrix effects (including ion suppression) as compared to ESI [133]. APCI is 
often used in clinical assays due to its compatibility with liquid chromatography [133]. 
Furthermore, MALDI utilize laser to ionize the analytes and it is appropriate for detection 
analytes directly from nonextracted samples, e.g. tissue surface/slices (so called mass 
spectrometry imaging), or spotted lipid extracts on MALDI plate [86]. Also, it can be used in 
LC-MS or shotgun lipidomics [11].   
 
Electrospray (ESI) 
Electrospray is sensitive ion source where ions are formed in solution or liquid phase 
and that works under atmospheric pressure [133]. Importantly, it is one of the softest 
platforms for ion ionization and the most popular quantitative technique for lipidomics [73] 
and clinical purposes [133]. The principle of ESI is as follows (see Figure 8). The sample is 
nebulized through a highly charged stainless steel capillary using heated nebulizing gas 
(typically nitrogen), producing fine aerosol [86]. It results in evaporation of the solvent and 
ionization of the molecules after which the ions [86] formed by desolvation [11] enter the 
mass spectrometer [86]. Therefore ESI source behaves as an electrophoretic device that 
selectively ionize a certain type of ions that is conducting with a continuously equilibrating 
mobile phase [73]. The technique is ideal for easily ionizated molecules [115] but ionization 
of less ionizable lipid can be enhanced by derivatization [147,148]. Of note, molecular ions 
can be formed in the source of the mass spectrometer without fragmentation [115]. 
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Electrospray can be used for quantitative and qualitative analysis of all lipid species [86], for 
analysis of polar compounds [136] or complex dimers [73] and it allows simultaneous but 
specific analysis of multiple species with good sensitivity as well [115]. It is used in shotgun 
or LC-MS arrangement [11] while ESI mass spectrometry detection increases with decreasing 
liquid chromatography flow rate [58].  
 
Figure 8. Schematic diagram of an electrospray source showing formation of pseudo-molecular ions. (A) The geometry of a tandem or 
quadrupole–quadrupole–linear ion trap instrument. (B) The sample (in aqueous-organic solvent) is sprayed through a charged capillary and 
the solvent is evaporated by the sheath of nebulizing gas. (C) Pseudo-molecular ions form by explosive fragmentation as the droplet dries. 
Adapted from [115]. 
 
Electrospray ionization has several advantages [137]. First, ESI can act as a separation 
device to selectively ionize a certain category of lipid molecular species based on the charge 
property of lipid class [73]. Therefore, it separates different lipid species with high efficiency 
without prior chromatographic separation [73] however ESI can be easily coupled to liquid 
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chromatography for further separation of analytes as well [93,115]. Second, ESI has a high 
ionisation efficiency, the limit of detection can be even fmol/µl  [73], and wide dynamic 
range [149]. Third positive is that quantification of individual molecular species is possible 
through direct comparison of ion peak intensities of analyte and internal standard or through 
the    peak-area measurement in the case of LC-MS [73]. Furthermore, there is a nearly linear 
relationship between an ion peak intensity of analyte and the concentration of that 
compound [149]. On the other hand, the main limitation of ESI is the occurrence of              
ion-suppression (matrix) effects that is caused by additives in the mobile phase (acids, bases) 
and coeluting impurities from biological samples. Unfortunately matrix effect influences the 
sensitivity of instrument but it can be minimized through sample clean-up by solid phase 
extraction or small sample volume (i.e. 2-10 µl). Practically, blank injection during 
measurement helps to monitor the background contamination [93]. 
 
Analyzers 
Mass spectrometry analysers used in lipidomics are mainly Orbitrap [73], triple 
quadrupole and time-of-flight. These analysers combine high resolution with mass accuracy 
and provide high specificity of detection [86]. Time-of-flight (TOF) mass analyser separates 
ions based on their different flight times over a defined distance or flight path where travel 
time is calibrated to the m/z value [133]. TOF analyser measures all ion masses for each ion 
pulse [133] and detects unlimited m/z [121]. Moreover, it offers high sensitivity and capability 
of accurate and precise quantitative measurements [133]. Triple quadrupole and Orbitrap 
analysers are described below. 
Hybrid MS is a spectrometer with combination of different mass filters (quadrupole, 
time-of-flight, ion trap etc.) and it can provide data-depending scanning. This approach can 
select one or more ions of interest for subsequent fragmentation (i.e. the product ion scan is 
performed for these selected ions) and thus it gives more structural information [86]. Hybrid 
instruments are for example QTRAP (for details see below) or Q-Orbitrap. The second 
mentioned combines a quadrupole with Orbitrap mass analyser while quadrupole performs 
precursor ion selection and Orbitrap product ion analysis. Q-Orbitrap can be used for protein 
sequencing and proteomic or metabolomic screening [133]. 
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Triple quadrupole (QQQ) 
Single quadrupole mass analyser consists of a set of four conducting rods arranged in 
parallel, with a space in the middle; the opposing pairs of rods are electrically connected to 
each other. This type of mass analyser separates ions based on the stability of their flight 
trajectories through an oscillating electric field in the quadrupole. The field is generated when 
a radio frequency (RF) voltage is applied between one pair of opposing rods within the 
quadrupole and direct current (DC) offset voltage is applied to the other pair of opposing rods. 
Then only ions of a certain m/z will have a stable flight path through the quadrupole in the 
resulting electric field; all other ions will have unstable trajectories and will not reach the 
detector. The RF and DC voltages can be fixed in a way that the quadrupole acts as a mass 
filter or analyte-specific detector for ions of a particular m/z. Alternatively, the analyst can 
scan for a range of m/z values by continuously varying the applied voltages. Single 
quadrupole mass spectrometer contains a single mass analyser and it can only measure ions 
formed in the instrument source [133].  
A tandem quadrupole mass spectrometer, often called a triple quadrupole, consists of 
two quadrupole mass analysers separated by a collision cell (see Figure 9) [133]. The 
principle of triple quadrupole and multiple reaction monitoring mode (MRM) is following. 
Ion of interest is isolated in the first mass analyser (first quadrupole) and fragmented in 
a collision cell (second quadrupole) using gas, e.g. nitrogen or argon. Then product ions are 
scanned and selected by a second analyser (third quandrupole) and related back to their 
precursor ion [60,87,93] (see Figure 9). The pairs of precursor and product ions are called 
mass transitions and when the electric fields and collision energy are held constant, only 
analyte ions having a specified mass transition are able to reach the detector [133].  
Triple quadrupole is sensitive, fast-scanning and reproducible with high dynamic 
range [111] and specificity [133]. Moreover, the signals are scanned many times per second 
and therefore the chromatographic peaks in the case of LC-MS are very reproduced and 
intensive [87]. The drawback of QQQ is limited resolution and lower sensitivity at higher 
acquisition rates and when scanning a wide mass range. Therefore it cannot be sufficient for 
metabolite identification based on the measured mass [86]. On the other hand, triple 
quadrupole is best for sensitive targeted quantitative analysis using MRM as it isolates and 
targets analytes of interest and excludes signal from the background matrix [111]. Of note, 
multidimensional mass spectrometry is combination of different scan types (neutral loss scan, 
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product and precursor ion scan-for details see below) applied on the same sample in triple 
quadrupole [86]. 
 
 
Figure 9. Multiple reaction monitoring mass spectrometry A schematic of a triple quadrupole mass spectrometer commonly used in multiple  
reaction monitoring mass spectrometry (MRM-MS) analysis; Q represents a quadrupole in a triple quadrupole mass spectrometer. Relative 
intensities of measured transitions from three targeted peptides eluting at different retention times are monitored by MRM-MS (coloured in 
red, blue and green). MS/MS in Q2 illustrates the fragments in the second quadrupole Q2 (collision cell) for one of the three peptides (blue). 
An MRM-MS assay offers multiplexing capability of many target analytes in a single high-pressure liquid chromatography run. Adapted 
from [150]. 
 
 
Ion traps 
Ion trap mass analysers use an electromagnetic field to capture or ―trap‖ ions inside 
the mass analyser. There are multiple configurations of ion traps including a 3D ion traps 
(Paul ion trap), a linear ion trap (2D trap), an electrostatic trap (Orbitrap), or a magnetic    
field-based trap (ion cyclotron resonance) [133]. Ion traps have relatively slow acquisition 
rate and thus they are not ideal for fast chromatography [86]. Also, some ion traps have 
tandem mass spectrometry (MS
n
) capability (MS
n
 is discussed below). 
First, a 3D ion trap basically works on the same principle as a quadrupole mass 
analyzer as it uses static DC current and RF oscillating electric fields but with hardware 
configured differently. The parallel rods are replaced with two hyperbolic metal electrodes 
(end caps) facing each other, and a ring electrode placed halfway between the end cap 
electrodes while ions are trapped in a circular flight path based on the applied electric field. 
Second, a linear ion trap uses a set of quadrupole rods coupled with electrodes on each end to 
facilitate the ion trapping. This configuration gives the linear ion trap a dual functionality, 
i.e. it can be used as a quadrupole mass filter or an ion trap. An ion cyclotron resonance trap 
uses a strong magnetic field to induce a radial orbit of ions, where the frequency of orbit in 
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the magnetic field is a function m/z for the ion. Finally, an Orbitrap mass spectrometer is 
a high-resolution instrument that consists of an inner spindle-like electrode and an outer 
barrel-like electrode. It stores all ions in stable flight path and detects them on the basis of 
their detected frequencies which is related to m/z [133]. Moreover, Orbitrap detects unlimited 
m/z [121], determinates the exact mass of the compounds and also resolves isobaric species 
and isotope fine structures [86]. 
Mass spectrometers that include an ion trap analyser are the most commonly used for 
qualitative work (e.g., metabolite or protein identification, and screening applications) [133] 
or for structural characterization of molecules [86]. Although examples of ion trap mass 
analysers for quantitative analysis do exist, their use in quantitative clinical MS to date is 
limited [133]. Ion traps are not also appropriate for precursor ion scanning, neutral loss 
scanning or multiple reaction monitoring modes (these modes are more discussed below) 
because they do not have two separate analysers [115]. 
We utilized hybrid instrument QTRAP mass spectrometer that combines a quadrupole 
mass analyser with a linear ion trap in our research. QTRAP is popular in toxicology 
screening for unknown agents or in quantitative analyses when the linear trap is operated as 
a quadrupole [133]. Specifically, our instrument QTRAP 5500 from Sciex is very flexible and 
sensitive [115] and it is capable of carrying out several mass spectrometry modes, i.e. Q1 MS, 
Q3 MS, product ion, precursor ion, neutral loss or gain, multiple reaction monitoring, 
enhanced MS, enhanced product ion, enhanced resolution, MS
3, TripleTrap™ scanning 
modes [151]. Furthermore, the instrument has the ability to switch polarity in less than 50 ms 
i.e. without delay in the cycle, and it has dwell time as low as 2 ms without losses in 
sensitivity [111]. On the other hand its limitation lies in the upper limits of mass scan range 
which is m/z 1000 for the trap and m/z 1250 for collision cell. For example, its limit of 
detection for a single phospholipid species is approximately 0.125 pmol (100 pg) using 
neutral loss scanning mode while precursor ion scanning mode gives 10-fold higher 
sensitivity in a case of 10 µl as an injection volume [115].  
 
1.2.3.3. Mass spectrometry modes 
Selected ion monitoring (SIM) detects ion intensities in a survey mode in which only 
a single m/z or limited m/z ratio is transmitted for quantification. Advantage of this platform is 
simple instrumentation because it is not a tandem technique. On the other hand monitored m/z 
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could represent combination of analyte and their isobaric counterparts and that leads to less 
specific identification and inaccurate quantification [121].  
Tandem mass spectrometry (MS
n
) involves multiple (-n) rounds of mass spectrometry 
in which precursor ions are either analysed or fragmented again n-times [86] (see Figure 10) 
while it results in product ions studied through a second mass analyser [93]. Tandem mass 
spectra are complicated because they contain fragments from all co-isolated precursors and 
from chemical background [74]. The plus is that MS
n
 can significantly reduce baseline noise 
by double filtering [121] but on the other hand it cannot separate isomers and isobaric 
compounds [152]. Also, in-source decay that generates fragments of the same mass-to-charge 
ratio occurs in MS
n
 and therefore suitable chromatographic technique is needed before MS 
detection in some cases [152]. In practice, MS
2
 identifies the analytes by their specific 
fragmentation [57,74] whereas MS
3
 is useful for enhanced structural identification of 
individual ions [115].   
 
Figure 10. MS/MS. Conventional and MS/MS modes of analysis in a triple-quadrupole mass spectrometer are shown. (A) In the normal 
scanning mode, all ions of a certain m/z range are transmitted through the first two quadrupoles for mass analysis in the third quadrupole. 
From this MS spectrum, a parent ion is selected for fragmentation in the collision cell. (B) In MS/MS mode, the parent ion is  selectively 
transmitted into the collision chamber and fragmented, and the resulting daughter ions are resolved in the third quadrupole. Adapted from 
[153]. 
 
Selected (SMR) or multiple reaction monitoring (MRM) modes use two mass 
analysers as static mass filters to monitor a particular fragment ion (i.e. product ion) of 
a selected precursor ion on triple quadrupole-like instruments (for details see above Triple 
quadrupole). The specific pair of m/z values associated with the precursor and product ions is 
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referred to as a ´transition´[11]. SRM monitors one transition while MRM monitors multiple 
transitions [133]. Both modes have high specificity and sensitivity of detection and enable us 
to analyse hundreds of compounds [59]. MRM is appropriate for quantifying certain 
predetermined species [115], i.e. target analyses [11], rather than investigating broader profile 
of analytes [115]. Specifically, multiple reaction monitoring mode is used for analysis of 
specific fatty acids in negative-ion mode or for headgroup analysis in positive ion mode [115].  
Product ion scan (EPI) involves selecting a molecular ion of interest (i.e. precursor 
ion) in the first mass analyser, fragmenting it in the collision cell by collision with gas and 
detecting all the resultant fragment ions (i.e. product ions) in the second mass analyser (see 
Figure 11). The drawback of EPI is that it is time consuming as analyses have to be done 
individually for all components of a complex mixture. Further, this tandem mass technique is 
utilized for structural identification because it enables us to obtain m/z and information about 
the composition of the parent molecular ion (e.g. the position of acyl chain in the glycerol 
moiety) and information of functional group or their location within the carbon acyl 
chain [115]. In practice, product ion spectra can be acquired from different lipid class because 
lipids have diverse head groups and we got a various fragment ions from them [73].  
Precursor ion scan (PIS) consists of the identification of molecular species that give 
rise to a particular product ion after fragmentation (see Figure 11). Specifically, the first 
analyser scans all the precursor ions through mass range and second analyser detects only m/z 
that belongs to specific fragment of analyte of interest [115]. The selected fragment ion 
corresponds with a common fragment ion of the precursors and thus all the precursors that 
produce specific fragments are monitored [11]. PIS is tandem mass spectrometry 
approach [11] that is appropriate for determination of analytes that have fragments with same 
polarity as analyte itself and for targeted detection or comparative analyses between 
controlled samples [115]. Of note, precursor ion scan is less quantitatively accurate than 
MRM [115].  
Neutral loss scan (NLS) is a tandem mass technique where first analyser scans all 
precursor ions and the second mass analyser scans fragment ions set at an offset from the first 
analyser (see Figure 11). The offset corresponds to a common neutral loss from the precursor 
ions and all that neutral losses are monitored [11]. NLS is a powerful tool for a targeted 
detection but it is not commonly used for quantitative analysis because it is less accurate than 
for example MRM [115].   
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Figure 11. Advanced MS routines for targeted detection of molecular species. (A) Product ion scanning (EPI) selects a specific molecular 
ion in Q1, fragments it in Q2, and scans to determine the m/z ratios of the product ions in Q3. (B) Precursor ion scanning mode scans 
through the mass range in Q1; at each step the molecular ions are fragmented in Q2, and Q3 is fixed to select the passage of a specific 
product ion, which can then be related to the precursor (parent) ion. (C) Neutral loss scanning mode scans both Q1 and Q3 simultaneously 
but with a fixed mass offset between them, so that precursor ions that fragment in Q2 by loss of a specific neutral fragment can be identified. 
Adapted from [115].  
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1.2.3.4. Shotgun technique 
The total lipid extracts of cells or tissues are directly infused in nanoliter-range into 
a mass spectrometer in shotgun mass spectrometry [74]. Then analyses are performed at 
constant concentration of extracted solution [11,121]. Moreover, shotgun approach has 
´unlimited´ time and thus ions can be subjected to numerous MS scans and the measurement 
provides hundreds of spectra [11]. Also, every single peak in the full scan mass spectrum 
could represent one or more molecular species and identification of that species is achieved 
by knowledge of their product ion spectra or building block-related neutral loss 
scan/precursor ion scan spectra [73]. Of note, the complexity of sample can be reduced by 
sample preparation (e.g. extraction of different lipid classes) or selective ionization [11]. 
Shotgun MS is a high-throughput approach [11], its reproducibility is as high as 
95% [137,154] and it also provides high accuracy of analysis [73]. Conversely, the limitations 
of that technique are ion-suppression effects [58,81,86], inability to distinguish certain 
isobaric or isomer species, unreliability to quantify low abundant lipids and difficulty in 
identifying unknown lipids [86]. Shotgun mass spectrometry can be used for global analyses 
of individual lipid species [73].   
 
1.2.3.5. Quantitative analysis 
The goal of quantification in analytical chemistry is to determine the relative or 
absolute abundance of analyte. Relative quantification measures the pattern changes of 
analytes of interest while absolute quantification determines the mass levels of individual 
analytes and derives total amount of them. The effective strategy to quantify the analytes of 
interest is to use external or internal standards. External standards are utilized for 
establishment of calibration curve while quantification is achieved by comparing the ion 
intensity of analyte with that curve. The advantage of the approach is that there is no concern 
of overlapping analyte and standard because they are analysed separately. On the other hand, 
it is necessary to have identical experimental conditions for both analyses [121].  
Internal standard (IS) is analogue of the analyte and it is added to sample during 
sample preparation process (ideally as soon as possible). The sample with internal standard is 
analysed simultaneously in one analysis and therefore any possible variation during the entire 
process is compensated [121]. Nevertheless sometimes diverse retention times for internal 
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standard and analyte itself can be detected due to different ion suppression [86]. Using 
internal standard is very simple and accurate [121], it helps to reduce experimental errors [73] 
and it is also a useful approach when multiple peaks for one transition appear [63]. Internal 
standards are utilized for absolute quantification [115]. Concentration of analyte can be 
carried out using conventional equation according to where the analyte´s concentration is 
directly related to concentration of internal standard [155]. In practice, concentration of each 
individual molecular species can be calculated by comparing the ion-peak intensities (shotgun 
approach) or peak areas (in LC-MS technique) of analyte and internal standard [11,73]. 
Importantly, the internal standard should represent the physical properties of the entire 
chemical class, be chemically similar to the analyte of interest [114] and should not be in 
original sample or in very minimal level [121]. Using isotopically labelled or non-endogenous 
standards as internal standards is advantageous [121]. Isotopologue form of analyte is 
identical to the endogenous molecule except for mass [87] and therefore they are ionisable 
similarly [121]. Also, they can act as a carrier preventing the loss of trace amounts of analyte 
during extraction and analysis [156] or be utilized to confirm the presence of endogenous 
analyte in sample [87]. Unfortunately, stable isotope analogues do not exist for every 
biomarkers, sometimes only deuterated and structural analogues are available. Deuterated 
standards are separated slightly but significantly differently as compared to analyte of interest 
and using structural analogue is unsuitable because they have a different retention time and 
ionization properties than the analyte of interest [87]. In practice, dimyristoyl (C14:0/C14:0) 
or diheptadecanoyl (C17:0/C17:0) are very rare in mammalian tissues and thus they can be 
used as internal standard in lipid analyses [115].  
 
2. METHODS 
 
We adapted and optimized several methods based on liquid chromatography and mass 
spectrometry for our research [111,157–160]. First, metabolomic methods include 
a 10minutes long method, that is able to separate acylcarnitines (AC) and amino acids (AmA), 
and a more general method that is suitable for determination of other metabolites than AC and 
AmA. Subsequently, lipidomic methods comprise an analysis of eicosanoids and 
endocannabinoids (in 16 minutes) and a method for measurement of FAHFA compound. All 
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analyses were performed using an UPLC system (UltiMate 3000 Binary RSLC System, 
Thermo) coupled to QTRAP 5500 (Sciex, California, USA) mass spectrometer. 
 
2.1. METABOLOMIC LC-MS METHODS 
 
2.1.1. Acylcarnitine´s and amino acid´s 10minutes method 
 
The method is based on HILIC Kinetex column, 50x2.1 mm, 1.7 µm (Phenomenex, USA) 
heated to 25 °C and it is able to separate 57 acylcarnitines and 21 amino acids in 10 minutes. 
Mobile phase A consists of 90/10 (v/v) acetonitrile and buffer, and phase B of 90/10 (v/v) 
water and buffer, while the buffer is 20 mM ammonium formate with pH 4. Gradient elution 
of mobile phase is in Figure 12. Briefly, analysis starts at 100 % of mobile phase A, then it 
decreases to 75 % of A and after that it rises to 99 % of A. Finally, gradient goes back to 
100 % of A where it stayes till the end of analysis, i.e. time 9.5 min. Flow rate of mobile 
phase is 0.5 ml/min and injection volume of sample is 3 µl. AmA and AC are determined in 
positive multiple reaction monitoring (MRM) mode (list of MRM transitions is in Table 1) 
with electrospray as ion source. Importantly, we validated the method in sense of precision 
and accuracy according to [155]. Validation in practice, plasma samples from two mice 
strains, C57BL/6J and A/J, were divided into triplicates and analysed separately in three days 
to assess the inter-assay variability, and as a triplicate within one run to assess the intra-assay 
variability. The validation analyses were performed the same way as normal analyses.  
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Figure 12. Elution gradient of mobile phase in 10minutes  method. Mobile phase A consists of 90/10 (v/v) acetonitrile and buffer, and phase 
B of 90/10 (v/v) water and buffer. The buffer is 20 mM ammonium formate (pH 4). Flow rate of mobile phase is 0.5 ml/min and injection 
volume of sample is 3 µl. HILIC Kinetex column heated to 25 °C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
 
Table 1. MRM transitions for acylcarnitines and amino acids in 10minutes method. CX is acylcarnitine with X carbons in acylchain, CXDC 
is dicarboxylcarnitine with X carbons in acylchain. CXOH is hydroxycarnitine with X carbons in acylchain. CX:Y is acylcarnitine with X 
carbons and Y double bonds in acylchain. CX:Y-OH is acylcarnitine with X carbons and Y double bonds in hydroxyacylchain. Analyte-Dx is 
deuterated analyte. Glycine-
12C15N is isotopic analogue of glycine .Mobile phase A consists of 90/10 (v/v) acetonitrile and buffer, and phase 
B of 90/10 (v/v) water and buffer. The buffer is 20 mM ammonium formate (pH 4). Flow rate of mobile phase is 0.5 ml/min and injection 
volume of sample is 3 µl. HILIC Kinetex column heated to 25 °C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
ID Q1 Q3 DP CE CXP 
Glycine 76.0 30.1 60 19 16 
Glycine-
12
C
15
N 79.1 32.1 60 19 16 
Alanine 90.2 44.1 60 24 16 
Alanine-D4 94.1 48.2 60 24 16 
Serine 106.0 60.0 60 15 16 
Proline 116.1 70.1 70 21 16 
Valine 118.1 72.0 70 25 16 
Threonine 120.0 74.0 60 15 16 
Proline-D7 123.0 77.0 70 21 16 
Valine-D8 126.1 80.1 70 25 16 
Hydroxyproline 132.0 68.2 60 30 16 
Leucine/Isoleucine/Hydroxyproline 132.0 86.1 50 16 16 
Ornithine 133.0 70.1 50 23 16 
Asparagine 133.1 74.1 55 25 16 
Aspartic acid 134.0 116.0 60 13 16 
Leucine-D3 135.1 89.1 50 16 16 
Aspartic acid-D3 137.0 119.0 60 13 16 
Ornithine-D6 139.0 76.1 50 23 16 
Glutamine+Lysine 147.0 84.0 60 25 16 
Lysine 147.0 67.0 50 30 16 
Glutamic acid 148.1 130.0 60 13 16 
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Methionine 150.0 133.0 50 13 16 
Methionine-D3 153.0 136.1 51 13 16 
Glutamic acid-D5 153.0 135.0 60 13 16 
Histidine 156.1 109.9 46 19 16 
Carnitine 162.1 85.0 60 29 10 
Phenylalanine 166.0 120.1 50 20 16 
Carnitine-D9 171.0 85.0 60 29 10 
Phenylalanine-D5 171.1 125.2 50 20 16 
Arginine 175.1 70.0 55 35 16 
Citrulline 176.1 113.0 31 23 16 
Citrulline-D2 178.1 115.0 31 23 16 
Arginine-D7 182.1 77.1 55 35 16 
Tyrosine 182.1 136.0 55 21 16 
Tyrosine-D4 186.1 140.1 55 21 16 
C2 204.2 84.9 51 27 16 
Tryptophan 205.1 146.1 51 23 16 
C2-D3 207.0 85.0 51 27 16 
C3 218.1 85.0 51 27 16 
C3-D3 221.1 85.1 51 27 16 
C4:1 230.1 85.1 56 29 16 
C4 232.1 85.1 56 29 16 
C4-D3 235.0 85.0 56 29 15 
C5:1 244.2 85.0 50 29 16 
C5 246.1 85.1 66 29 16 
C3DC.C4OH 248.2 85.0 50 31 16 
C5-D9 255.2 85.0 66 29 16 
C6:1 258.2 85.0 57 33 15 
C6 260.1 85.1 51 31 16 
C4DC.C5OH 262.2 85.0 60 31 16 
C6-D3 263.0 85.0 51 31 15 
C5DC 276.1 85.1 70 35 16 
C5DC-D6 282.0 85.0 70 35 15 
C8:1 286.2 85.0 60 31 16 
C8 288.2 85.0 72 34 16 
C6DC. C7OH 290.2 85.0 60 31 16 
C8-D3 291.0 85.0 72 34 15 
C7DC 304.0 85.0 66 39 15 
C10:2 312.2 85.0 70 35 16 
C10:1 314.2 85.0 70 35 16 
C10 316.2 84.9 79 38 16 
C10-D3 319.0 85.0 79 38 15 
C12:1 342.3 85.0 70 35 16 
C12 344.3 85.1 81 41 16 
C12-D3 347.0 850 81 41 15 
C14:2 368.2 85.0 75 41 16 
C14:1 370.2 85.0 80 45 16 
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C14 372.2 85.0 81 47 16 
C12DC 374.3 85.0 86 45 15 
C14-D3 375.0 85.0 81 47 15 
C14:2-OH 384.3 85.0 81 49 15 
C14:1-OH 386.3 85.0 81 50 15 
C14-OH 388.3 85.0 80 47 16 
C16:2 396.3 85.0 83 51 15 
C16:1 398.3 85.0 80 48 16 
C16 400.3 85.0 90 47 16 
C16-D3 403.0 85.0 90 47 15 
C16:2-OH 412.3 85.0 86 53 15 
C16:1-OH 414.3 85.0 100 55 16 
C16-OH 416.3 85.0 100 55 16 
C18:3 422.3 85.0 98 57 15 
C18:2 424.3 85.0 100 55 16 
C18:1 426.3 85.0 100 55 16 
C18 428.3 85.1 105 51 16 
C18-D3 431.0 85.0 105 51 15 
C18:2-OH 440.3 85.0 100 55 16 
C18:1-OH 442.3 85.0 100 55 16 
C18-OH 444.3 85.0 100 55 16 
C20:5 446.3 85.0 120 55 15 
C20:4 448.3 85.0 120 55 16 
C20:3 450.4 85.0 120 55 15 
C20:2 452.4 85.0 102 60 15 
C20:1 454.4 85.0 100 55 15 
HpODE 456.3 85.0 100 55 15 
C20 456.4 85.0 120 55 16 
HETE 464.3 85.0 100 55 15 
C22:6 472.3 85.0 120 55 16 
C22:5 474.4 85.0 106 65 15 
C22:4 476.4 85.0 110 55 15 
HpETE 480.3 85.0 100 55 15 
C16DC 524.0 85.0 100 55 16 
C18DC 570.0 85.0 100 55 16 
 
 
2.1.2. General metabolomic approach 
 
More general metabolomic method detects as many as 254 metabolites 
(e.g. phosphorylated compounds) including AC and AmA in 40 minutes. The platform utilizes 
aminopropyl column, 150x2 mm, 3 µm (Phenomenex, USA) heated to 25 °C and the mobile 
phase acetonitrile (phase A) and alkaline buffer (phase B), i.e. ammonium acetate (20 mM, 
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pH = 9.45). The buffer was freshly prepared every 2 weeks to prevent pH change and was 
controlled before analysis. Elution gradient of mobile phase is in Figure 13 while the flow 
rate is 0.3 ml/min. One µl of sample was determined in both positive and negative mode with 
scheduled multiple reaction monitoring mode (MRM transitions are in Table 2).  
 
Figure 13. Elution gradient of mobile phase in general 40 minutes metabolomic method. The mobile phase A is acetonitrile and phase B is 
ammonium acetate (20 mM, pH = 9.45). The flow rate of mobile phase is 0.3 ml/min and one µl of sample is analysed. Aminopropyl column 
heated to 25 °C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
 
Table 2. MRM transitions for metabolites in general 40 minutes metabolomic method in both positive and negative mode. CX is acylcarnitine 
with X carbons in acylchain, CXDC is dicarboxylcarnitine with X carbons in acylchain. CXOH is hydroxycarnitine with X carbons in 
acylchain. CX:Y is acylcarnitine with X carbons and Y double bonds in acylchain.  The mobile phase A is acetonitrile and phase B is 
ammonium acetate (20 mM, pH = 9.45). The flow rate of mobile phase is 0.3 ml/min and one µl of sample is analysed. Aminopropy l column 
heated to 25 °C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
ID Q1 Q3 DP CE CXP 
Cholesterol 387.1 105.0 146 21 10 
N- acetylserotonin 218.9 159.9 101 21 14 
Nicotinamide 122.9 79.9 10 27 8 
Urea 61.1 44.2 60 25 10 
C22:6 472.3 85.0 106 65 15 
C20:5 446.3 85.0 102 60 15 
C20:4 448.3 85.0 102 60 15 
C18:2 424.3 85.1 89 54 15 
C18:1 426.4 85.1 89 55 15 
C16:1 398.3 85.1 84 51 15 
C14:1 370.3 85.1 78 47 15 
Creatinine 113.9 86.0 46 15 10 
C16 400.3 85.1 84 51 15 
C14 372.3 85.1 86 45 15 
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C18 428.4 85.1 96 63 15 
C12 344.3 85.1 73 44 15 
C12:1 342.3 85.1 73 44 15 
C10 316.2 85.1 56 37 15 
C8 288.2 85.1 66 33 15 
C8:1 286.2 85.1 63 37 15 
C6 260.2 85.1 56 27 15 
C16DC 524.0 85.0 103 62 15 
C5 246.2 85.1 46 29 15 
C4OH 248.1 85.1 55 32 15 
Homocystine 268.9 135.9 56 15 12 
C6DC 290.2 85.1 63 37 15 
C5:1 244.2 85.1 55 31 15 
C4 232.2 85.1 46 29 15 
C3 218.1 85.1 46 29 15 
C5DC  276.2 85.1 61 35 15 
C6OH 276.2 85.1 61 35 15 
C5OH 262.2 85.1 58 33 15 
Serotonin 160.0 115.0 90 25 15 
C4DC 262.2 85.1 58 33 15 
C2 204.1 85.1 41 27 15 
C3DC  248.1 85.1 55 32 15 
Leucine /Isoleucine/ 
Allo-isoleucine/Norleucine 132.0 85.9 46 15 10 
Phenylalanine 165.9 119.9 36 19 12 
Valine 117.9 72.1 56 17 8 
Methionine 149.9 104.0 41 15 10 
Taurocholate 516.0 337.1 120 33 15 
Creatine/5-aminolevulinate 131.9 89.9 61 19 8 
Tryptophan 204.9 145.8 41 25 14 
Carnitine 161.9 102.9 56 23 10 
Proline 115.9 69.9 31 21 8 
Hydroxyproline 132.0 68.2 31 30 8 
3-aminoisobutyrate 104.0 86.1 56 11 8 
Alanine /Sarcosine 89.9 44.1 51 23 6 
Dopamin 137.0 91.0 90 25 15 
Tyrosine 181.9 136.0 46 19 12 
Homocysteine 135.9 91.0 136 33 10 
Threonine/homoserine 119.9 73.9 41 15 8 
Glycine 75.9 29.9 41 27 8 
Glutamine 146.9 83.9 66 25 10 
Asparagine 132.9 74.1 36 21 8 
Serine 105.8 60.0 16 15 8 
Histidine 155.9 110.0 46 19 10 
Choline 104.3 60.0 36 23 8 
3-nitrotyrosine 227.1 181.1 60 20 10 
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Ornithine 132.9 115.6 51 13 12 
Lysine 146.9 84.0 66 23 10 
5-hydroxytryptophan 220.9 161.9 46 25 16 
Glycerol 93.0 57.0 30 12 10 
Adrenaline 183.9 100.8 61 23 10 
NAD 664.0 136.0 71 69 15 
Glutamate 147.8 83.9 41 23 8 
Cystine 240.9 151.8 36 19 20 
Cysteine 121.9 58.9 120 31 10 
Glutathione reduced 307.9 178.9 41 17 16 
Noradrenaline 170.0 107.0 61 23 10 
Phosphocreatine 211.7 90.1 26 21 10 
FAD 786.0 348.0 76 31 15 
NADH 666.0 649.0 61 25 15 
AMP 348.0 136.0 90 50 10 
Glutathione oxidized 613.0 355.0 71 33 15 
ADP 428.0 136.0 90 30 10 
Acetyl-CoA 809.7 303.0 36 41 15 
CoA 768.0 261.0 90 50 13 
Propionyl-CoA 824.0 317.3 36 50 13 
Butyryl-CoA 838.0 331.3 36 50 13 
Malonyl-CoA 854.0 347.0 36 41 15 
Succinyl-CoA 868.1 361.1 36 40 15 
Acetoacetyl-CoA 852.0 345.0 36 50 13 
3-hydroxy-3-methylglutaryl-CoA 910.0 408.0 36 43 15 
ATP 508.0 136.0 90 40 10 
Acetylcholine 146.1 87.1 40 20 8 
Histamine 112.2 95.1 90 20 15 
Anandamide 348.3 62.1 90 30 15 
Glutamate 148.0 84.0 46 17 16 
Asparate 134.0 73.9 45 15 30 
cGMP-F1 346.1 152.1 70 27 10 
cGMP-F2 346.1 135.1 70 65 8 
Palmitoyl-CoA 1006.4 499.4 40 50 13 
 
ID Q1 Q3 DP CE CXP 
Palmitic acid 255.1 45.1 -145 -54 -7 
Palmitoleic acid 253.2 253.2 -145 -50 -7 
Stearic acid 283.3 283.3 -145 -50 -7 
Linolenic acid 277.3 277.3 -145 -50 -7 
Linoleic acid 279.3 279.3 -145 -50 -7 
Cyclic-AMP 328.1 134.0 -80 -36 -9 
Cyclic-GMP 344.0 150.0 -80 -36 -9 
FA 22:6 (DHA) 327.2 283.2 -140 -15 -15 
Arachidonic acid 303.2 259.2 -140 -17 -15 
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Oleic acid 281.2 263.2 -140 -25 -15 
FA 20:5 (EPA) 301.2 257.2 -140 -15 -15 
Glucose/Fructose/Galactose/Mannose 178.9 88.9 -40 -12 -9 
Glyoxylate 73.0 73.0 -30 -6 -15 
Taurine 123.8 79.9 -45 -28 -7 
Lactose/Maltose/Melibiose/Sucrose 340.9 161.0 -55 -12 -11 
Lactose/Maltose/Melibiose/Sucrose 340.9 179.0 -40 -15 -15 
Arginine 173.0 131.1 -55 -22 -17 
Citrulline 174.0 131.2 -40 -16 -9 
Oxalate 88.9 70.9 -45 -14 -9 
Lactate 88.9 43.0 -30 -16 -7 
Acetoacetate/2-oxobutanoate/Succinate semialdehyde 100.8 57.0 -30 -12 -7 
2-oxoglutarate 144.9 101.0 -30 -10 -7 
Isopentenyl diphosphate 245.0 79.0 -30 -34 -15 
CDP-choline 487.0 428.0 -80 -18 -15 
Glucuronic acid 193.0 113.0 -45 -18 -15 
Aspartate 132.0 88.1 -35 -16 -7 
4-aminobutyrate 102.0 102.0 -10 -6 -15 
Pyruvate 86.9 43.1 -45 -12 -7 
CDP-ethanolamine 445.0 79.0 -45 -82 -15 
N-argininosuccinate 288.9 132.0 -70 -28 -9 
Ethanolamine phosphate 139.8 78.9 -20 -16 -7 
Phosphocreatine 209.8 78.8 -70 -16 -3 
N-acetylglutamate 187.9 102.0 -45 -24 -9 
2-hydroxyglutarate 146.9 128.9 -25 -16 -13 
Suberate 172.9 111.0 -35 -20 -9 
Glutaconate/Ketoleucine/Mevalonolactone/ 
3-methyl-2-oxopentanoate 128.9 85.0 -36 -12 -7 
Oxaloacetate/Glutarate/Ethylmalonate 130.8 86.8 -37 -16 -9 
Methylsuccinate 131.0 87.0 -35 -15 -10 
Succinate/Methylmalonate 116.8 73.0 -35 -14 -9 
Sebacic acid 200.9 139.0 -65 -26 -13 
Malate 132.9 115.0 -35 -15 -7 
Glycerol-3-phosphate 170.9 78.9 -35 -34 -9 
Malonate/3-hydroxybutanoate 102.9 59.0 -30 -14 -7 
3-hydroxybutyrate 102.9 59.0 -30 -14 -7 
Hydroxypyruvate 102.8 59.0 -35 -12 -5 
Dihydroxyacetone phosphate 169.0 79.0 -40 -36 -15 
Fumarate/Caproic acid 114.9 71.0 -38 -13 -7 
Glyceraldehyde-3-phosphate 168.8 97.1 -40 -10 -5 
Glucose-1-phosphate/Fructose-6-phosphate/ 
Galactose-1-phosphate/Glucose-6-phosphate 258.8 78.9 -40 -58 -9 
Xylulose 5-phosphate 229.0 97.0 -35 -18 -15 
CMP 322.0 79.0 -75 -62 -15 
UMP 323.0 79.0 -60 -60 -15 
GDP-Fucose 588.0 442.0 -75 -34 -15 
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Geranyl diphosphate 313.0 79.0 -25 -45 -15 
GMP 362.0 79.0 -65 -62 -15 
NADP 742.0 619.9 -90 -24 -15 
Isocitrate 190.8 110.9 -40 -18 -11 
Citrate 191.1 87.0 -40 -18 -11 
3-phosphoglycerate/2-phosphoglycerate 184.8 78.9 -20 -50 -7 
Aconitate 172.9 84.9 -35 -18 -7 
UDP-glucuronic acid 579.0 403.0 -75 -32 -15 
Phosphoenolpyruvate 166.8 78.9 -35 -24 -7 
UDP 403.0 79.0 -60 -76 -15 
Fructose-1,6-bisphosphate 339.1 96.9 -35 -30 -5 
CDP 426.0 158.9 -90 -33 -15 
GDP 442.0 79.0 -70 -82 -15 
NADPH 744.0 407.9 -90 -39 -15 
CTP 481.9 158.9 -70 -44 -15 
UTP 483.0 79.0 -65 -90 -15 
1,3-bisphosphoglycerate 265.0 79.0 -20 -37 -7 
GTP 522.0 79.0 -60 -90 -15 
Cholate 407.2 343.3 -145 -44 -5 
Glycocholate 464.2 73.9 -140 -68 -11 
Taurocholate 514.2 80.0 -165 -100 -11 
Chenodeoxycholate 391.2 391.2 -140 -44 -8 
Glycochenodeoxycholate 448.2 73.9 -105 -50 -10 
Taurochenodeoxycholate 498.2 79.9 -195 -110 -5 
Ribose 148.8 88.9 -30 -14 -17 
3-methylglutaconic aciduria 143.0 55.0 -65 -20 -9 
Prostaglandine E2 315.2 271.2 -70 -25 -15 
Ribose-5-phosphate/Xylulose-5-phosphate 228.8 96.8 -45 -20 -13 
Sedoheptulove-7-phosphate 288.9 97.1 -53 -23 -17 
Fructose-6-phosphate 258.9 97.1 -50 -15 -17 
Glyceraldehyde-3-phosphate 168.9 79.1 -42 -20 -15 
Erythrose-4-phosphate 198.9 79.0 -43 -25 -17 
Pantothenate 218.0 88.0 -51 -14 -16 
UDP-glucose 564.8 323.1 -54 -26 -15 
2-oxoglutarate 145.0 73.8 -45 -19 -7 
6-phosphogluconate 275.0 97.0 -41 -20 -24 
1,3-bisphosphoglycerate 265.0 167.2 -41 -18 -29 
 
 
Acylcarnitines and amino acids elute at the beginning of elution gradient and therefore 
we could shorten the elution gradient to 12 min (Figure 14) to determine primarily them. In 
brief, 5 % of mobile phase B is at the beginning of analysis, then mobile phase B elevates to 
70 % and after up to 95 %. Finally the gradient goes back to 5 % of B where it stayes till 
59 
 
12 min. The twelve minutes method enables separation of 31 AC, 24 AmA, and 
27 metabolites (glucose, cholesterol etc.) in positive MRM mode.   
 
Figure 14. Elution gradient of mobile phase in 12minutes metabolomics method. The mobile phase A is acetonitrile and phase B is 
ammonium acetate (20 mM, pH = 9.45). The flow rate of mobile phase is 0.3 ml/min and one µl of sample is analysed. Aminopropy l column 
heated to 25°C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
 
 
2.2. LIPIDOMIC LC-MS METHODS  
 
2.2.1. Eicosanoid´s and endocannabinoid´s method 
 
We are able to separate 150 eicosanoids and endocannabinoids in 16 minutes. The method 
is based on octadecyl Kinetex column, 150x2.1 mm, 1.7 μm (Phenomenex, USA) heated to 
50 °C and mobile phase consists of two parts. Mobile phase A is 30/70 (v/v) acetonitrile and 
1.3 mM CH3COONH4 and part B is a mixture of acetonitrile and isopropanol 50/50 (v/v). 
Elution gradient of mobile phase is in Figure 15 and the flow rate is 0.3 ml/min. Analytes 
were determined in 10 µl of sample in negative MRM mode (MRM transitions are in 
Table 3).  
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Figure 15. Elution gradient of mobile phase in eicosanoids and endocannabinoids method. Mobile phase A is 30/70 (v/v) acetonitrile and 
1.3 mM CH3COONH4 and part B is a mixture of acetonitrile and isopropanol 50/50 (v/v). The flow rate of mobile phase is 0.3 ml/min. 
Injection volume of sample is 10 µl. C18 Kinetex column heated to 50 °C. UPLC system (Thermo) and MS QTrap 5500 (Sciex).  
 
Table 3. Multiple reaction monitoring transitions in eicosanoids and endocannabinoids method. FA is fatty acid. 12-HHT is 12-hydroxy-
heptadecatrienoic acid. Y-oxo-ODE is Y-keto-octadecadienoic acid. X-HODE is X-hydroxy-octadecadienoic acid. 15d-PGX is 15-
deoxyprostaglandin X (15-hydroxy-oxo-prostatetraenoic acid). PGX is prostaglandin X. X-HEPE is X-hydroxy-eicosapentaenoic acid. X-
oxo-ETE is X-oxoicosa-tetraenoic acid. X-HETE is X-hydroxy-eicosatetraenoic acid. X,Y-EET is X,Y-epoxy-eicosatrienoic acid. X-HETrE is 
X-hydroxy-eicosatrienoic acid. LTX is leukotriene X (dihydroxy-eicosapentanenoic acid). 20-COOH-AA is 20-carboxyarachidonic acid. RvX 
is Resolvin X. HXY is hepoxilin Y (hydroxyl-epoxy-eicosatrienoic acid). X,Y DHET is X,Y-dihydroxyeicosatrienoic acid. X-HDoHE is X-
hydroxy-docosahexaenoic acid. CUDA is 12-[(cyclohexylcarbamoyl)amino]dodecanoic acid. X,Y-EpDPE is X(Y)-epoxy-docosapentaenoic 
acid. dhk-PGE2 is 15-keto-13,14-dihydroprostaglandin E2. X-OH-LTB4 is X-hydroxy-leukotriene B4. X,Y,Z-TriHETrE isX,Y,Z-Trihydroxy-
eicosatrienoic acid. X,Y-DiHDPA is X,Y-dihydroxy-docosapentaenoic acid. Mobile phase A is 30/70 (v/v) acetonitrile and 1.3 mM 
CH3COONH4 and part B is a mixture of acetonitrile and isopropanol 50/50 (v/v). The flow rate of mobile phase is 0.3 ml/min. Injection 
volume of sample is 10 µl. C18 Kinetex column heated to 50 °C. UPLC system (Thermo) and MS QTrap 5500 (Sciex).  
ID Q1 Q3 DP CE CXP 
FA 16:1 (Palmitoleoyl) 253.2 235.2 -140 -25 -15 
FA 18:3 (γLinolenoyl) 277.2 233.2 -140 -20 -15 
12-HHT  279.0 163.0 -60 -30 -15 
FA 18:2 (Linoleoyl) 279.2 261.2 -140 -26 -15 
FA 18:1 (Oleoyl) 281.3 263.3 -140 -25 -15 
13-oxo-ODE  293.0 113.0 -100 -30 -15 
9-oxo-ODE  293.0 185.0 -90 -25 -15 
13-HODE  295.2 195.2 -90 -25 -15 
9-HODE  295.2 171.1 -90 -25 -15 
FA 20:5 (EPA) 301.2 257.2 -80 -15 -15 
FA 20:4 (AA) 303.2 259.2 -140 -17 -15 
EPA-D5 306.0 262.0 -100 -15 -15 
AA-D8  311.3 267.0 -110 -20 -15 
15d-PGJ3 313.0 269.0 -80 -15 -15 
15d-PGJ2  315.2 271.3 -80 -15 -15 
18-HEPE 317.0 259.0 -65 -18 -23 
15-HEPE  317.0 219.0 -65 -19 -8 
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11-HEPE  317.0 121.0 -90 -24 -15 
12-HEPE  317.0 179.0 -70 -21 -15 
8-HEPE  317.0 127.0 -90 -25 -15 
9-HEPE  317.0 149.0 -90 -20 -15 
5-HEPE  317.0 115.0 -60 -22 -11 
15-oxo-ETE  317.0 113.0 -70 -25 -15 
12-oxo-ETE  317.0 153.0 -70 -25 -15 
5-oxo-ETE  317.0 203.0 -70 -25 -15 
9-HETE  319.0 151.0 -80 -20 -15 
14,15-EET  319.0 219.0 -80 -15 -15 
11,12-EET  319.0 167.0 -90 -20 -15 
8,9-EET  319.0 155.0 -90 -20 -15 
5,6-EET  319.0 191.0 -60 -20 -15 
20-HETE  319.2 289.2 -95 -25 -15 
18-HETE  319.2 261.0 -100 -25 -15 
17-HETE  319.2 247.0 -100 -25 -15 
16-HETE  319.2 189.0 -100 -25 -15 
15-HETE  319.2 219.2 -70 -15 -18 
11-HETE  319.2 167.2 -80 -20 -15 
12-HETE  319.2 179.2 -80 -20 -15 
8-HETE  319.2 155.1 -80 -20 -15 
5-HETE  319.2 115.1 -80 -20 -22 
15d-PGJ2-D4  319.2 275.3 -110 -20 -15 
15-HETrE  321.0 221.0 -90 -21 -15 
FA 22:6 (DHA) 327.2 283.2 -140 -15 -15 
5-HETE-D8  327.3 116.1 -80 -20 -15 
15-HETE-D8 327.3 226.0 -80 -20 -15 
12-HETE-D8 327.3 183.0 -80 -20 -15 
FA 22:5 (DPA) 329.3 285.3 -80 -15 -15 
8, 9 EET-D11  330.0 155.0 -90 -20 -15 
PGJ3 331.2 269.0 -50 -20 -15 
δ12-PGJ3 331.2 269.0 -100 -20 -15 
DHA-D5 332.0 234.0 -110 -20 -15 
LTB5 333.0 195.0 -90 -25 -15 
5,15-diHEPE 333.0 115.0 -110 -22 -17 
20-COOH-AA 333.1 289.1 -125 -22 -15 
PGB2  333.2 271.2 -60 -20 -15 
δ12-PGJ2 333.2 271.0 -110 -15 -15 
PGA2  333.2 235.3 -50 -20 -15 
PGJ2  333.2 233.1 -50 -20 -15 
15d-PGD2  333.2 271.2 -50 -20 -15 
RvE3 333.3 201.1 -40 -22 -17 
RvE2 333.3 253.2 -40 -22 -17 
8,15-diHETE  335.0 127.0 -80 -25 -15 
HXB3  335.0 183.0 -70 -20 -15 
5,6-diHETE  335.0 163.0 -90 -25 -15 
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5,15-diHETE  335.2 115.2 -110 -22 -17 
LTB4  335.2 195.1 -120 -22 -17 
HXA3 335.2 171.1 -110 -20 -15 
17,18-diHETE 335.3 247.2 -90 -25 -15 
14,15-diHETE 335.3 207.2 -90 -25 -15 
14,15-DHET  337.0 207.0 -90 -25 -15 
11,12-DHET  337.0 167.0 -90 -25 -15 
8,9-DHET  337.0 127.0 -90 -30 -15 
5,6-DHET  337.0 145.0 -95 -25 -15 
CUDA 339.2 214.1 -100 -20 -15 
2,3-dinor-6-keto-PGF1α 341.0 135.0 -90 -30 -15 
17-oxo-DHA 341.5 111.0 -90 -20 -15 
20-HDoHE  343.0 241.0 -90 -20 -15 
16-HDoHE  343.0 233.0 -105 -19 -15 
17-HDoHE  343.0 245.0 -80 -20 -18 
13-HDoHE  343.0 221.0 -90 -17 -15 
14-HDoHE  343.0 205.0 -70 -21 -15 
10-HDoHE  343.0 181.0 -80 -17 -15 
11-HDoHE  343.0 149.0 -90 -19 -15 
8-HDoHE  343.0 109.0 -100 -20 -15 
7-HDoHE  343.0 141.0 -40 -18 -13 
4-HDoHE  343.0 101.0 -40 -18 -13 
19,20-EpDPE 343.5 281.2 -80 -20 -15 
16,17-EpDPE 343.5 273.5 -80 -15 -15 
8,9-DHET-D11 348.0 127.0 -120 -30 -15 
PGE3 +D3 349.2 269.0 -75 -25 -15 
PGD3  349.2 189.0 -75 -25 -15 
RvE1 349.2 195.1 -80 -24 -16 
LXA5  349.0 115.0 -90 -25 -15 
PGF3α 351.0 193.0 -105 -30 -15 
dhk-PGE2  351.0 235.0 -70 -25 -15 
dhk-PGD2  351.0 207.0 -70 -25 -15 
LXB4 351.2 221.1 -90 -30 -21 
LXA4 351.2 235.1 -95 -22 -11 
PGE2+D2 351.2 271.2 -70 -25 -15 
PGD2  351.2 189.0 -70 -25 -15 
20-OH-LTB4 351.3 195.2 -90 -25 -15 
dhk-PGF2α 353.0 291.0 -90 -25 -15 
PGF2α 353.2 193.2 -80 -30 -15 
8-iso-PGF2α 353.2 309.3 -80 -30 -15 
PGE1 353.3 317.2 -80 -25 -15 
PGD1 353.3 273.0 -80 -25 -15 
11,12,15-TriHETrE 353.3 167.1 -100 -30 -15 
PGF1α 355.0 293.0 -95 -30 -15 
PGD2-D4 355.2 275.2 -70 -25 -15 
8-iso-PGF2α-D4 357.0 197.0 -80 -30 -15 
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10,17-DiHDPA 359.0 153.0 -70 -20 -15 
Maresin1 359.2 250.1 -40 -22 -17 
19,20-DiHDPA  361.0 229.0 -90 -25 -15 
PGF2α-D9 362.0 193.0 -80 -30 -15 
20-COOH-LTB4 365.3 347.2 -90 -25 -15 
11-dh-TXB2 367.1 305.1 -70 -25 -15 
TXB3 367.2 169.1 -70 -25 -15 
11-dh-TXB3 367.2 169.1 -70 -25 -15 
TXB2  369.2 169.1 -75 -25 -15 
6-keto-PGF1α 369.3 163.2 -85 -35 -15 
TxB1 371.0 171.0 -70 -25 -15 
6k-PGF1α-D4 373.3 167.1 -85 -35 -15 
RvD2 375.2 141.2 -90 -24 -13 
RvD1  375.2 215.2 -90 -22 -13 
RvD2-D5 380.0 175.0 -80 -40 -15 
LTE4  438.2 333.2 -120 -30 -15 
LTD4  495.0 177.0 -90 -25 -15 
LTC4  624.3 272.1 -120 -30 -15 
 
 
2.2.2. FAHFA analysis 
Branched fatty acid hydroxy fatty acids (FAHFA) are determined on octadecyl 
stationary phase, 150x2.1 mm, 1.7 μm (Phenomenex, USA) warmed up to 50 °C. The mobile 
phase is 30/70 (v/v) acetonitrile and water with 0.01% acetic acid, pH 4 (part A) and 
50/50 (v/v) acetonitrile and isopropanol (part B). Serum samples were analysed by gradient 
elution in 25 minutes (Figure 16) and structural analysis was done by isocratic elution with 
20 % of mobile phase A in 60 minutes. Flow rate of mobile phase is 0.2 ml/min and injection 
volume of sample is 10 µl. DHAHLA compound was measured in negative multiple reaction 
mode, specifically 605.4>327.2, and the optimal collision energy was chosen as -35 V while 
declustering potential was -130 V. MRM transitions for FAHFA compouds are in Table 4.  
 
Table 4. MRM transitions for FAHFA compounds. Q1, precursor ion; Q3, product ion; FA, quantifier ion; HFA and HFA-H2O, qualifier 
ions. PAHSA is palmitic acid hydroxystearic acid, DHAHLA is docosahexaenoic acid hydroxylinoleic acid and DHAHDHA is 
docosahexaenoic acid hydroxydocosahexaenoic acid. Adapted from [99]. 
ID Q1 [M-H]
- 
Q3 FA Q3 HFA Q3 HFA-H2O 
PAHSA 537.5 255.2 299.3 281.3 
DHAHLA 605.4 327.2 295.2 277.2 
DHAHDHA 653.4 327.2 343.2 325.2 
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Figure 16. Elution gradient of mobile phase in FAHFA analysis. Mobile phase A is 30/70 (v/v) acetonitrile and water with 0.01% acetic acid 
(pH 4) and mobile phase B is 50/50 (v/v) acetonitrile and isopropanol. Flow rate of mobile phase is 0.2 ml/min. Column C18 heated to 
50 °C. Injection volume of sample is 10 µl. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
 
 
2.3. OTHER METHODS 
 
2.3.1. Measurement of glycerol and non-esterified FAs 
 
Media after co-incubation of adipocytes and macrophages were stored in -20 °C until time 
of analysis. Then free glycerol and non-esterified FAs were measured in media by 
spectrophotometric method using kits, specifically NEFA-HR(2), ACS-ACOD Method 
(Wako Chemicals USA Inc., USA) and Glycerol GLY (Randox, UK). 
 
2.3.2. DNA measurement 
 
DNA was measured in all parts of white adipose tissue (WAT) and WAT itself using 
Hoechst fluorescence stain. Hoechst increases in fluorescence in the presence of DNA, 
binding specifically and quantitatively [161]. The process in brief, TRIS, EDTA (both 
pH 7.4), water, 10% SDS and proteinase K solution were added to samples and heated to 
56 °C for a night. Then we added buffer NaCl-Na2HPO4-EDTA (pH 7.4) and Hoechst 
(H33258) to samples and swayed them for 4 hours. Finally, we measured the fluorescence of 
sample by fluorescence spectrophotometer (Perkin-Elmer LS50B) with excitation at 356 nm 
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and emission at 458 nm. Of note, concentration of DNA was calculated using calibration 
curve prepared with DNA standard (Sigma-Aldrich, Czech Republic).  
 
2.3.3. ELISA and quantitative polymerase chain reaction (qPCR) 
 
The concentration of IL-6 was determined using IL-6 ELISA kit (Cayman Chemicals). 
The mRNA levels of cytokines IL-6, TNF-α, IL-1β and PTGS2 were determined by       
qPCR-based gene expression analyses that were performed according to standard protocols 
while the levels of transcripts were evaluated in total RNA isolated from cells.  
 
2.4. PREPARATION OF SAMPLE 
 
2.4.1. Samples for metabolomic methods 
 
2.4.1.1. Acylcarnitine´s and amino acid´s 10minutes method 
One µl of plasma sample was combined with extraction solution (i.e. methanol and 
0.1% formic acid) and mixture of internal standards (MassChrome Amino Acids and 
Acylcarnitines kit, Chromsystems, Gräfelfing, Germany). Mass chrome kit includes labelled 
AC and AmA and represents an expanded screening panel of inborn metabolic disorders 
based on tandem mass spectrometry [68]. Afterwards, the sample was homogenized in 
an ultrasonic bath (Ultrasonic-cleaner US-10, Lab. Companion, USA) for 60 s burst, 
centrifuged (5 min, 15 000 g, 4 °C) and the supernatant was used for LC-MS measurement.  
 
2.4.1.2. General metabolomic method 
White adipose tissue was homogenized using a bead mill MM400 (Retsch, Germany) and 
extracted with 75% acetonitrile in which the internal standards (MassChrome Amino Acids 
and Acylcarnitines kit, Chromsystems, Gräfelfing, Germany) were dissolved. Serum and 
plasma samples were extracted in the same way apart from homogenization. The medium 
from co-culture experiment was replaced by 30% acetonitrile after the attempt. Macrophages 
that covered the well plates were frozen in liquid nitrogen and stored in -80 °C until analyses 
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when frozen cells with extraction solution were scraped off the wells and transferred to 1.5 ml 
tubes. After that, extracts of WAT, serum, plasma or cell samples were homogenized in 
ultrasonic bath (Ultrasonic-cleaner US-10, Lab. Companion, USA) for 60 s burst and 
centrifuged for 5 min (15 000 g, 4 °C). Finally, the supernatant was used for liquid 
chromatography-mass spectrometry analyses. 
 
2.4.2. Samples for lipidomic methods 
 
2.4.2.1. Liquid/liquid extraction 
Bligh&Dyer and Folch methods are two well established liquid/liquid extraction 
approaches. Both utilize solution of chloroform, methanol and water and they were performed 
according to standard protocols [117,118] in our research.  
 
2.4.2.2. Eicosanoid´s and endocannabinoid´s method  
Solid phase extraction procedure was utilized to extract eicosanoids and 
endocannabinoids from WAT or cell samples. First in macrophages, the medium was replaced 
by 50% methanol after the co-culture experiment and macrophages grown on wells were 
frozen in liquid nitrogen and stored in -80 °C until analyses. Then frozen cells with extraction 
solution were scraped off the wells and transferred to 1.5 ml tubes. Subsequently, internal 
standards (their list is in Table 5), cold water and methanol were added to samples while final 
concentration is 15% methanol. Also, we added 46 µl hydrochloric acid to acidify 2.5 ml 
sample. SPE was carried out with Strata-X columns (60 mg, 3 ml, Phenomenex) that were 
washed by ethylacetate and conditioned with methanol and water. The samples were 
intercepted on columns and washed by water and hexane and elution of sample was achieved 
by adding methylformate and methanol. Finally, samples were evaporated in Speedvac and 
residues were dissolved in 30% acetonitrile and analysed by LC-MS. Second, WAT with 
methanol were homogenized in bead mill MM400 (Retsch, Germany) and centrifuged for 
5 min (15 000 g, 4 °C). Then internal standards were added to samples and extraction 
procedure continued as described before. Adipocytes and SVF isolated from WAT were 
extracted same apart from homogenization as well as CD11b positive and CD11b negative 
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cells that were separated from SVF. Of note, it is crucial to keep all samples at ice to avoid the 
degradation of samples during extraction procedure. 
 
Table 5. List of internal standards (IS). Analyte-Dx is deuterated analyte with x-times deuterium. EPA is eicosapentaenoic acid. AA is 
arachidonic acid. DHA is docosahexaenoic acid. PGX is prostaglandin X . 15d-PGX is 15-deoxyprostaglandin X (15-hydroxy-oxo-
prostatetraenoic acid). 8-iso-PGX is 8-iso-prostaglandin X. 6k-PGX is 6-ketoprostaglandin X. X-HETE is X-hydroxy-eicosatetraenoic acid. 
X,Y-EET is X,Y-epoxy-eicosatrienoic acid. X,Y DHET is X,Y-dihydroxyeicosatrienoic acid. RvX is Resolvin X. 
IS 
EPA-D5 
AA-D8  
15d-PGJ2-D4  
5-HETE-D8  
15-HETE-D8 
12-HETE-D8 
8,9-EET-D11  
DHA-D5 
8,9-DHET-D11 
PGD2-D4 
8-iso-PGF2α-D4 
PGF2α-D9 
6k-PGF1α-D4 
RvD2-D5 
 
 
2.4.2.3. FAHFA analysis 
DHAHLA´s extraction was based on Yore et al. [111]. Serum samples were extracted by 
liquid/liquid and solid phase extraction. First LLE, dichlormethane and methanol as organic 
phase and chilled citric acid buffer with pH 3.6 as water phase were added to sample (the final 
ratio is 2:1:1). The acidic pH in buffer suppresses the ionization of carboxylic group in 
DHAHLA and also lipids go willingly to organic phase. After, the organic phase was dried in 
Speed-vac (Savant SPD121P; ThermoFisher Scientific) and dissolved in dichloromethane. 
This sample underwent SPE that was performed on column Strata SI-I Silica columns (55 µm, 
70 A, Sigma). The columns were conditioned by hexane, sample was applied on them and 
elution of DHAHLA was achieved by ethyl acetate. Finally, samples were evaporated, 
dissolved in methanol and analysed by liquid chromatography and mass spectrometry. Cells 
68 
 
were homogenized using a bead mill MM400 (Retsch, Germany) at first and then extraction 
procedure continued as described above. Importantly, LC-MS analyses have to be done 
immediately to avoid the decay of the DHAHLA compound because ester bond between 
DHA and HLA is very sensitive to hydrolysis. 
Extraction of milk samples is slightly different than extraction of serum samples. First, 
milk samples (300 µl) were warmed to 25 °C in water bath and homogenized for 10 s in 
ultrasonic bath to disrupt fat globule membranes and ensure the consistent quality of sample. 
Later on, LLE with dichlormethane, methanol and citric acid buffer was performed as 
described before. The organic phase was collected, water phase was re-extracted and then 
organic phase was pooled, dried in a Speed-vac and dissolved in dichloromethane. 
Unfortunately, pulsed sonication as well as citric acid buffer in LLE lead to the formation of 
foamy cakes full of casein micelles that are very abundant in colostrum/transient milk samples 
and it complicated the collection of organic phase during extraction. After that solid phase 
extraction was performed on Hypersep column (500 mg/10 mL, 40–60 μm, 70 Å, Thermo) 
that provides cleaner samples even though it is related to lower DHAHLA yield. The analyte 
of interest was eluted from SPE columns with ethyl acetate as previously and it was 
concentrated using Speed-vac, dissolved in methanol and immediately analysed by LC-MS.  
 
2.5. SAMPLES 
 
2.5.1. Animals  
 
Both mice strains, i.e. mice of the AJ and the C57BL/6J genetic background, fed 
standard maintenance diet (STD; Ssniff R/M-H diet, Ssniff Spezialdieten GmbH, Soest, 
Germany), containing 13.0 kJ/g as proteins (33%), carbohydrates (58%), and lipids (9%) or 
corn oil-based high-fat diet (HFD; lipids ~35% wt/wt) or diet with omega-3 PUFA 
concentrate (46% wt/wt DHA, 14% wt/wt EPA; product EPAX 1050 TG; EPAX, Alesund, 
Norway) replacing 15% wt/wt of dietary lipids (HFF diet).  
Rats fed standard chow diet (control) (3300 kcal kg
–1
 ; Panlab, Barcelona, Spain) or 
cafeteria (high caloric) diet. The cafeteria diet includes: biscuits with a Majorcan sausage 
('sobrasada') and with liver pate, salted peanuts, chocolate, candies, carrots, fresh bacon, 
cheese, sugared milk (20% w/v) and a Majorcan pastry ('ensaimada').  
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2.5.2. Cells 
 
RAW 264.7 and bone marrow-derived macrophages were grown according to standard 
protocols as well as 3T3L1 murine cell model of adipocytes and human adipocytes (hMADs). 
Adipocytes and SVF were liberated from white adipose tissue of mice by collagenase solution 
according to published method [104] using Krebs Ringer bicarbonate medium with 
5mM glucose and 4% BSA (fraction V, FA free, Sigma Aldrich). Specifically,       
collagenase-digested samples were passed through a sterile 250 µm nylon mesh and the 
suspension was centrifuged at 4 g for 5 min. The pellet was collected as SVF and the top 
buoyant layer was washed twice and collected as floating adipocytes.  
Moreover, we utilized immunoprecipitation method using CD11b antibody bonded to 
a magnet to separate adipose tissue macrophages (ATM) from SVF. CD11b (Mac-1, αMβ2) is 
expressed on bone marrow-derived immune cells and is responsible for facilitating cell 
adhesion and transmigration across the endothelium or epithelium. Also, it traffics to the 
inflammation sites to mediate the inflammatory response [162]. Separation of ATM in 
practice, anti-CD11b antibody was coupled to magnetic beads, added to SVF and then CD11b 
positive cells were bonded to magnetic beads. Using a magnet, we were able to separate both 
CD11b positive (i.e. macrophages, monocytes) and negative (i.e. lymphocytes, endothelial 
and vascular cells) cells and analyse them separately. 
 
2.6. CHEMICALS 
 
All chemicals were purchased from Sigma-Aldrich (Prague, Czech Republic). Standard   
5-PAHSA was purchased from Cayman Pharma (Neratovice, Czech Republic). The standard 
of 13-DHAHLA was synthetized in the Institute of Organic Chemistry and Biochemistry of 
the Czech Academy of Sciences and the organic synthesis was performed according to 
Steglich esterification [163]. Importantly, we store DHAHLA standard in brown glass tube 
with argon atmosphere to avoid chemical oxidation of the compound.  
 
 
70 
 
3. RESULTS 
 
3.1. ANALYSES OF ACYLCARNITINES AND AMINO ACIDS 
 
3.1.1. Introduction 
We utilized mainly very sensitive approach UPLC-MS/MS to describe white adipose 
tissue (WAT) metabolism. At first, we wanted to find and optimize methods for analysis of 
acylcarnitines (AC) and amino acids (AmA). Acylcarnitines are intermediates of fatty acid 
and amino acid oxidation and they are important diagnostic markers [63]. Specifically,       
odd-numbered AC are newly discovered as potential markers of the metabolic syndrome and 
they influence development of insulin resistance [62] and impaired glucose tolerance in 
diabetes [63]. Therefore, our second goal was to reveal possible early biomarker of       
obesity-associated insulin resistance due to altered levels of AC and AmA in mice or rat´s 
plasma. 
 
3.1.2. Analytical highlights 
 
Acylcarnitine´s and amino acid´s 10minutes method. We have developed method 
based on hydrophilic interaction chromatography and high efficiency Kinetex 
chromatographic column. Mobile phase consists of water, acetonitrile and ammonium formate 
with acidic pH. AmA and AC are determined in positive MRM mode in less than 10 minutes 
while the method is able to separate 57 AC and 21 AmA. 
Validation of acylcarnitine´s and amino acid´s 10minutes method. We used mice 
strains C57BL/6J and A/J for validation of 10minutes method while it included precision and 
accuracy. In practice, samples of mice plasma were divided into triplicates and analysed 
separately in three days to assess the inter-assay validation, and as a triplicate within one run 
to assess the intra-assay validation. The validation analyses were performed same as normal 
analysis.  
Preparation of sample for acylcarnitine´s and amino acid´s 10minutes method. 
One µl of plasma sample was combined with methanol and 0.1% formic acid and mixture of 
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internal standards. Afterwards the sample was homogenized in an ultrasonic bath, centrifuged 
and the supernatant was used for LC-MS measurement.  
 
General metabolomic LC-MS method. The platform is based on aminopropyl 
column and mobile phase that consists of acetonitrile and alkaline ammonium acetate. The 
method analyses 254 metabolites including phosphorylated compounds as well as 
acylcarnitines and amino acids in 40 minutes. Shortened method for determination primarily 
AmA and AC takes only 12 min and enables to separate 31 AC, 24 AmA, and 27 metabolites 
(glucose, cholesterol etc.). All metabolites are measured in positive MRM mode. 
Preparation of sample for general metabolomic LC-MS method. Plasma samples 
were extracted with 75% acetonitrile with internal standards while then they were 
homogenized in an ultrasonic bath and centrifuged for 5 min. Finally, the supernatant was 
used for liquid chromatography-mass spectrometry analysis. 
 
Internal standards. We added mixture of deuterated labelled AC and AmA as 
internal standards (IS) to samples during extraction process to provide quantitative analysis. 
For analytes without corresponding IS, analyte-IS pairs were selected due to the most similar 
chemical structure and according to the closest retention times. 
 
3.1.3. Results  
 
3.1.3.1. Metabolomic methods 
 
In general 
The quantification of acylcarnitines is challenging because they have various species, 
e.g. positional isomers or isobaric compounds, and they also occur in low concentration [63]. 
Positional isomers have the same functional groups at different substituent positions [164] and 
therefore they have similar mass transition [63], for example hydroxybutyrylcarnitine C4OH 
can have hydroxyl group bonded on different carbons. On the other hand isobaric substances 
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are compounds of the same nominal mass but of different elemental composition [165]. 
Isobaric species are for example C4OH and C3DC or C5OH and C4DC. Structure of C4OH 
and C3DC is in Figure 17. Separation of these isobaric species is important because they 
describe different setting of metabolism as they come from various metabolic pathways. 
Acylcarnitines are usually analysed by direct infusion ESI-MS/MS which is very fast and 
cheap but it cannot separate isobaric species. Also, all acylcarnitines have a similar product 
ion (m/z 85) and thus it is difficult to separate them only by their mass using direct infusion 
mass spectrometry. For that reason, chromatographic separation before MS measurement can 
improve the analysis. Furthermore, several enhancements can be done, for example scheduled 
MRM mode provides shorter analysis time and more scan cycles per peak and ammonium 
acetate in mobile phase increases the ionization efficiency of the analysis of AC [63] etc.  
 
Figure 17. Hydroxybutyrylcarnitine C4OH and malonylcarnitine C3DC. Adapted from [166,167] 
 
We added mixture of deuterated labelled AC and AmA to samples as internal 
standards (IS) to provide quantitative analysis. Analyte-internal standard pairs are in Table 6. 
For analytes without corresponding IS, analyte-IS pairs were selected due to the most similar 
chemical structure and according to the closest retention time. Coelution of IS and 
corresponding analyte confirmed the analytes in sample. Importantly, we obtained the 
analyte´s concentration by comparing the analyte´s and IS´s peak area according to [63].  
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Table 6. Analyte-internal standard pairs utilized for quantitative analysis. CX is acylcarnitine with X carbons in acylchain, CXDC is 
dicarboxylcarnitine with X carbons in acylchain. CXOH is hydroxycarnitine with X carbons in acylchain. CX:Y is acylcarnitine with X 
carbons and Y double bonds in acylchain. CX:Y-OH is acylcarnitine with X carbons and Y double bonds in hydroxyacylchain. Analyte-Dx is 
deuterated analyte with x-times deuterium. Glycine-12C15N is isotopic analogue of glycine. 
Analyte IS Analyte IS 
 Carnitine Carnitine-D9 Glycine Glycine-
12
C
15
N 
 C2 C2-D3 Alanine Alanine-D4 
 C3 C3-D3 Serine Alanine-D4 
 C4:1 C4-D3 Proline Proline-D7 
 C4 C4-D3 Valine Valine-D8 
 C5:1 C5-D9 Threonine Alanine-D4 
 C5 C5-D9 Hydroxyproline Proline-D7 
 
C3DC,C4OH C4-D3 
Leucine+Isoleucine+ 
+hydroxyProline Leucine-D3 
 C6 C6-D3 Ornithine Ornithine-D6 
 C4DC,C5OH C5-D9 Asparagine Arginine-D7 
 C5DC C5DC-D6 Aspartic acid Aspartic acid-D3 
 C8:1 C8-D3 Glutamine+Lysine Arginine-D7 
 C8 C8-D3 Lysine Arginine-D7 
 C6DC, C7OH C8-D3 Glutamic acid Glutamic acid-D5 
 C10:2 C10-D3 Methionine Methionine-D3 
 C12:1 C12-D3 Histidine Arginine-D7 
 C12 C12-D3 Phenylalanine Phenylalanine-D5 
 C14:2 C14-D3 Arginine Arginine-D7 
 C14:1 C14-D3 Citrulline Citrulline-D2 
 C14OH C14-D3 Tyrosine Tyrosine-D4 
 C14 C14-D3 Tryptophane Tyrosine-D4 
 C16 C16-D3    
C16-1OH C16-D3    
C16OH C16-D3    
C18:2 C18-D3    
C18:1 C18-D3    
C18 C18-D3    
C18:2-OH C18-D3    
C18:1-OH C18-D3    
C18OH C18-D3    
C14DC C18-D3    
C16DC C18-D3    
C18DC C18-D3    
C20 C18-D3    
C20:4 C18-D3    
C22 C18-D3    
C24 C18-D3    
C26 C18-D3    
C22:6 C18-D3    
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Acylcarnitine´s and amino acid´s 10minutes method 
First method for analysis of acylcarnitines and amino acids was based on HILIC 
column and was able to separate 57 AC and 21 AmA in less than 10 minutes (for details see 
Analytical highlights or Methods). Validation study of that method comprised two mice 
strains because we processed both strains in our animal experiments. Validation was 
performed as follows according to [155]. In practice, samples of mice plasma were divided 
into triplicates and analysed separately in three days to assess the inter-assay validation, and 
as a triplicate within one run to assess the intra-assay validation. The validation analysis and 
sample preparation were performed same as common measurement. Of note, we excluded 
several analytes from validation study because evaluation of their peak areas was complicated 
due to asymmetrical and/or broad peaks. Specifically, we eliminated acylcarnitines C5DC, 
C12:1, C4:1, C5:1, C10:2, C8:1, C14:2-OH, C14:1-OH, C16:2-OH, C18:2-OH, C22:4 and 
amino acid glycine. As a result, overall average inter-assay precision obtained from 
measurement in different days was 9.43 % for acylcarnitines and 10.79 % for amino acids for 
both mice strains. Simultaneously, intra assay precision acquired from analyses of replicates 
was 8.65 % for AC and 5.55 % for AmA. All validation data are summarized in Table 7. 
Validation of standards can reveal potential changes in sample preparation. Nevertheless, 
analyses of sample replicates showed small alteration in AC´s and AmA´s concentrations and 
therefore it was not deemed necessary to analyse standards which is also in line with 
procedure in [155]. To sum up the validation study, 10minutes method was validated with 
good precision and accuracy up to 11 %. 
 
Table 7. Validation data for 10minutes method. Mobile phase A consists of 90/10 (v/v) acetonitrile and buffer, and phase B of 90/10 (v/v) 
water and buffer. The buffer is 20 mM ammonium formate (pH 4). Flow rate of mobile phase is 0.5 ml/min and injection volume of sample is 
3 µl. HILIC Kinetex column heated to 25°C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
 
 
Several rules were applied for qualitative analysis. For example it is known that 
retention time is shorter for AC with longer chain [71] and we saw this phenomenon in our 
  RSD of acylcarnitines (%) RSD of aminoacids (%) 
  Bl/6 strain AJ strain Overall Bl/6 strain AJ strain Overall 
inter assay validation 
(different days) 10.69 8.16 9.43 11.42 10.15 10.79 
 intra assay validation 
(in triplicates) 9.64 7.66 8.65 5.71 5.39 5.55 
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experiment as well (Figure 18). Moreover, we focused on separation of isobaric species that 
is challenging (for details see above). Chromatogram of isobaric species C4OH and C3DC is 
in Figure 19. It was complicated that both isobaric species weren´t visible in every sample 
and thus we had to find exact retention time for all that species to interpret the results 
correctly. In practice, chromatogram with both isobaric species gave us the retention times of 
that analytes and then we could easily find correct isobaric species in other chromatograms.       
 
Figure 18.Chromatogram of carnitine (C0) and acylcarnitines (C1-C4) measured by 10minutes method. Mobile phase A consists of 90/10 
(v/v) acetonitrile and buffer, and phase B of 90/10 (v/v) water and buffer. The buffer is 20 mM ammonium formate (pH 4). Flow rate of 
mobile phase is 0.5 ml/min and injection volume of sample is 3 µl. HILIC Kinetex column heated to 25°C. UPLC system (Thermo) and MS 
QTrap 5500 (Sciex). 
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Figure 19. Chromatogram of isobaric C4OH and C3DC measured by 10minutes method Mobile phase A consists of 90/10 (v/v) acetonitrile 
and buffer, and phase B of 90/10 (v/v) water and buffer. The buffer is 20 mM ammonium formate (pH 4). Flow rate of mobile pha se is 0.5 
ml/min and injection volume of sample is 3 µl. HILIC Kinetex column heated to 25°C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). 
 
 
General metabolomic method 
Afterwards, we improved the analyses due to our new UPLC-MS/MS metabolomic 
method. It is more general method separating AC, AmA and many other metabolites (up to 
254 compounds). The 10minutes method, previously used for measurement of AC and AmA, 
was fast and sensitive. Our new more general metabolomic approach with aminopropyl 
column (for details see Analytical highlights or Methods) was fast as well and it achieved 
better resolution than the previously used method for some AC and AmA. Also, certain peaks 
of acylcarnitines and amino acids were more symmetrical using this platform and it simplified 
peak integration process and saved peak review time.  
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3.1.3.2. Biological application 
 
In general 
We wanted to find potential candidates of AC and AmA which might be indicative of 
higher propensity for a dysmetabolic state or predict the predisposition to obesity in two 
rodent experiments. It may help early diagnosis and implementation of prevention strategies. 
For details of experiment´s methodologies see [68,168].   
 
Prediction an obesity in different mice genders  
First experiment strives to reveal which levels of AC and AmA predict the mice 
obesity, also with respect to different mice genders. The attempt was carried out on both 
genders of C57BL/6J mice that were fed high fat (HFD) or control diet. Plasma samples 
collected before and after weight gain were analysed by our validated AC´s and AmA´s 
10minutes method (for details see [68]).   
Gender-specific differences in response to high fat diet were observed in several levels 
of acylcarnitines and amino acids. For example plasma acylcarnitines´s levels of female mice 
were higher in case of C5, C14:2, C16:1-OH and lower in case of C18:1, C18:1-OH, C20:4 in 
comparison to male´s samples. Regarding amino acids, ornithine was increased in female 
mice while lysine was increased in HFD males. Importantly, long chain acylcarnitines and 
carnitine were the most discriminating factor in the pre-obese state of male mice. They 
represent complex early biomarker of obesity in male C57BL/6J mice together with even 
short AC species (C4, C6), branch-chained amino acid derived C4DC and amino acids 
tyrosine, alanine, ornithine and threonine. The situation was more complicated in the case of 
female mice. It seems that AC and amino acids do not represent the main process underlying 
the development of obesity and insulin resistance in female mice. Thus we could not 
determinate the biomarker of obesity in this gender.  
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Prediction an obesity in different rat´s models and feeding conditions 
The second experiment was based on two rat´s models with different metabolic 
programming outcomes and different feeding conditions. Specifically, attempt was carried out 
on offspring of dams fed a cafeteria diet during lactation (O-CAF, with a thin-outside-fat 
inside phenotype, model 1) and the offspring of diet-induced obese dams submitted to 
a dietary normalization before gestation (O-PCaf, non-altered phenotype, model 2). Plasma 
samples collected in fasting or ad libitum feeding state in all animal groups were measured by 
our general metabolomic methodology (for details see [168]).   
  Regarding model 1, PLS-DA score plot showed clear separated groups according to 
both, feeding/fasting conditions and to maternal diet during lactation (control or cafeteria 
diet). The variables with the highest contribution were the long-chain AC species C18, C18:1, 
C18:2, C16:1 and C16DC, and the amino acids glycine, alanine, isoleucine, serine and 
proline. These analytes predict the later dysmetabolic phenotype observed in the offspring and 
indicate a poor nutrition during lactation due to maternal unbalanced diet intake. 
O-PCaf and control animals presented a similar profile of circulating AC as well as 
AmA in model 2. On the other hand short-chain AC levels decreased and medium- and     
long-chain AC levels increased upon fasting. Thus, PLS-DA score showed significantly 
separated groups according to fed and fasting conditions but did not separate O-PCaf and 
control groups. 
 
3.1.4. Conclusion  
 
We established two UPLC-MS/MS methodologies for analyses of acylcarnitines and 
amino acids. Also, we aimed to find possible AC´s or AmA´s biomarkers of propensity to 
obesity in animal´s experiments using these platforms.  
First method is based on HILIC column and is able to separate about 80 analytes in 
less than 10 minutes. The method was validated with good precision and accuracy. We 
utilized this approach for mice experiment where we revealed several acylcarnitines, i.e. long 
chain ACs, carnitine, acylcarnitines C4 and C6, C4DC, as well as amino acids, i.e. tyrosine, 
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alanine, ornithine and threonine, that could serve as complex, gender-specific biomarker of 
propensity to obesity and partially also as biomarker of obesity-associated insulin resistance.  
Second, general metabolomic method is based on aminopropyl column and is able to 
separate up to 254 metabolites, including AC and AmA. This approach is relatively fast, 
sensitive and provides good peak shapes. Importantly, it simplified peak integration process in 
comparison to AC´s and AA´s 10minutes method. We utilized this platform for rat´s 
experiment where we uncovered that maternal intake of a cafeteria diet during lactation in rats 
entails an alteration in the plasma profile of AC and AmA. Specifically, changes were 
apparent in case of acetylcarnitine and medium- and long-chain AC, as well as in case of 
glycine, alanine, isoleucine, serine and proline, in the offspring, which is more evident under 
feeding conditions.  
 
3.2. INTERACTION OF ADIPOCYTES AND MACROPHAGES 
 
3.2.1. Introduction  
 
Subsequently, we wanted to describe WAT metabolism regarding mutual interaction 
between adipocytes and adipose tissue macrophages in WAT. Adipocytes are the main 
cellular components of adipose tissue and they are principal storage depots of the energy in 
form of TG droplets [169]. Almost all types of immune cells are present in WAT [170] but 
particularly adipose tissue macrophages (ATM) are associated with changes in metabolic state 
of the tissue [41–43]. It is known that the interaction between adipocytes and macrophages are 
key to the integrated control of adipose tissue inflammation and lipid metabolism in obesity 
but it is still unknown how the macrophages interact with neighbouring adipocytes [49]. Also, 
we specially focused on the effect of omega-3 PUFA on that interaction because it seems to 
be crucial for amelioration of low-grade inflammation [7]. We hypothesized that beneficial 
effect of omega-3 PUFA is caused by stimulation of M2 macrophages lipid processing. 
We performed several in vitro experiments where we co-incubated different types of 
macrophages and adipocytes or WAT explants, as source of fatty acids, to broaden our 
knowledge about WAT metabolism and we utilized mainly general metabolomic            
UPLC-MS/MS platform established before (see part 3.1.) for that. First, we described basic 
process in WAT, i.e. WAT lipolysis, by determination of free fatty acids and glycerol in 
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medium after the experiment using spectrophotometric method. Afterwards, we analysed both 
macrophages and adipocytes (or explants) after the experiments and therefore we gave insight 
the mutual interaction between these cells presented in WAT.  
 
3.2.2. Analytical highlights 
 
LC-MS method for analysis of eicosanoids and endocannabinoids. Eicosanoids and 
endocannabinoids are separated on octadecyl Kinetex column heated to 50 °C. Mobile phase 
consists of two parts, part A is 30/70 (v/v) acetonitrile and 1.3 mM CH3COONH4 and part B 
is mixture of acetonitrile and isopropanol 50/50 (v/v). The analytes are analysed in negative 
MRM mode in 16 minutes.  
Extraction of eicosanoids. Medium after the co-culture experiment was replaced by 
50% methanol and cells grown on wells were frozen in liquid nitrogen and stored in -80 °C 
until analyses. Lately, frozen macrophages with extraction solution were scraped off the wells 
and transferred into 1.5 ml tubes while internal standards, cold water, methanol and 
hydrochloric acid were added to samples. Afterwards solid phase extraction was done with 
Strata-X column washed by ethylacetate. The columns were conditioned with methanol and 
water and samples were applied on them. Then both column and sample were washed with 
water and hexane. Importantly, elution of sample was achieved by adding methylformate and 
methanol. Acquired samples were evaporated in Speedvac and residues were dissolved in 
30% acetonitrile and analysed by LC-MS.  
 
General metabolomic LC-MS method. See part 3.1. 
Sample preparation for general metabolomic LC-MS method. White adipose tissue was 
homogenized using a bead mill and extracted with 75% acetonitrile in which the internal 
standards were dissolved. Medium after co-culture experiment was replaced by 
30% acetonitrile and macrophages grown on well plate were frozen in liquid nitrogen. Then 
macrophages were scraped off from the wells and transferred into 1.5 ml tubes. Extracts of 
WAT or cell samples were homogenized in an ultrasonic bath and centrifuged for 5 min. 
Finally, the supernatant was used for liquid chromatography-mass spectrometry analysis. 
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Measurement of free fatty acids and glycerol. Medium after co-incubation was stored in     
-20 °C till analyses. Subsequently, free glycerol and non-esterified FAs in media were 
measured according to kit by spectrophotometric method.  
 
3.2.3. Results 
 
We co-incubated RAW macrophages (polarized to M1 or M2 state) and primary 
adipocytes from HF or HFF fed mice for 2h in first type of experiment. Then we prepared 
primary BDMD macrophages polarized into M1 and M2 form, or kept naïve (M0), 
respectively. These macrophages were exposed to explants from HF or HFF mice for 24h (for 
details see [99]). Both types of attempts simulated real situation in white adipose tissue.  
 
3.2.3.1. Lipolysis in WAT 
First, we focused on basic process of WAT, i.e. lipolysis. We measured non-esterified 
fatty acids and glycerol released during lipolysis in medium after the experiments by 
spectrophotometric methods. Our approach revealed that adipocytes alone or with M1 
macrophages released glycerol and fatty acid to the medium in ratio 1:1 (Figure 20           
panel A, B, C). It corresponds to the situation when 2 fatty acids from 3 are re-esterified back 
to TG. Same situation was for adipocytes from HF and HFF fed animals. Interestingly, HF 
adipocytes released more glycerol and fatty acids to the medium when exposed to M2 
macrophages. Specifically, the ratio for glycerol was 1.4 and for FA was 2.2 (Figure 20 
panel A, B, C). It suggests that less FA are re-esterified back to glycerol and the process of 
lipolysis and FA re-esterification is in favour of lipolysis and thus lipid storage is smaller than 
with M1 macrophages. It corresponds to the fact that M2 macrophages are predominant in 
lean WAT [1]. Co-incubation of M2 and HFF adipocytes denoted altered levels of glycerol 
and FA as well (Figure 20 panel A, B, C). Specifically, their significantly decreased levels, 
in compares to co-incubation of M2 and HF adipocytes, indicate higher FA re-esterification. 
Also, increased levels of M2 and HFF adipocytes, contrary to co-incubation of adipocytes 
with M1, suggest that less FA are re-esterified back to glycerol. Taken together, our results 
show that macrophages modulate the lipolysis and FA re-esterification in adipocytes. 
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Specifically, their modulation depends on polarization state of macrophages and it responses 
to dietary omega-3 PUFA supplementation. 
Of note, our previous mice experiment (see section 3.1.) revealed that non-esterified 
FA were higher in plasma of mice fed standard diet (STD) than mice fed high fat diet (HFD). 
It is in agreement with results from our in vitro experiment when we co-incubated 
macrophages and adipocytes from mice fed STD or HFD and where we elucidated higher 
levels of non-esterified FA in medium with adipocytes from mice fed STD as well (data not 
shown). 
 
Figure 20. Lipolysis in adipocytes co-incubated with macrophages. Freshly isolated adipocytes from HF-fed mice (HFA) or HFF-fed mice 
(HFFA) were incubated for 2 h either alone or in the presence of M1 or M2 polarized macrophages. Panel A: free glycerol, B: non-esterified 
FA were measured in the incubation media and re-esterification ratio (FA/glycerol) was calculated (panel C). Values are means ± SE, n = 
16, representative of 3 independent experiments. Panel D: relative levels of 2-linoleoylglycerol in adipocytes co-incubated with 
macrophages. Values are means±SE, n = 6, representative of 2 independent experiments. Adapted from [49]. 
 
3.2.3.2. Metabolic profile of macrophages and source of FA after their co-incubation 
We analysed both adipocytes and macrophages after their co-incubation by our 
general metabolomic approach to look for changes reflecting the interaction between them. 
The metabolic profile of adipocytes was not significantly altered by the co-incubation with 
macrophages when compared with macrophages. In contrast, macrophages responded 
dynamically to the presence of adipocytes (Figure 21) and therefore we discuss data obtained 
from them in further paragraphs.  
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Figure 21. Metabolic profile of macrophages after their co-incubation with adipocytes. X-HETE is X-hydroxy-eicosatetraenoic acid. X-
HEPE is X-hydroxy-eicosapentaenoic acid. X-HDoHE is X-hydroxy-docosahexaenoic acid. 15d-PGX is 15-deoxyprostaglandin X (15-
hydroxy-oxo-prostatetraenoic acid). PGX is prostaglandin X. Y-oxo-ODE is Y-keto-octadecadienoic acid. CX is acylcarnitines with X 
carbons in acylchain. TAG is triacylglycerol. DAG is diacylglycerol. CE is cholesterol ester. FA is fatty acid. EA is ethanolamine. X-HODE 
is X-hydroxyoctadecadienoic acid. LPA is lysophosphatidic acid. DHAP is dihydroxyacetone phosphate. GA3P is glyceraldehyde 3 -
phosphate.Fru-1,6-BP is fructosa-1,6-bisphosphate.  HMG-CoA is 3-hydroxy-3-methylglutaryl-CoA. GlcNAc is N-acetylglukosamin. The 
mobile phase A is acetonitrile and phase B is ammonium acetate (20 mM, pH = 9.45). The flow rate of mobile phase is 0.3 ml/min and  one µl 
of sample is analysed. Aminopropyl column heated to 25 °C. UPLC system (Thermo) and MS QTrap 5500 (Sciex). Adapted from [49]. 
 
 
 
Figure 22. Polarization and FA re-esterification in ATMs. Bone marrow-derived macrophages were kept naive M0, polarized into M1 or M2 
state using cytokines and co-incubated with WAT explants from HF (HFW) or HFF (HFFW) mice or without explants (none) for 24 h. 
Metabolomics analysis was performed as before. A: markers of polarization; B: acylglycerols containing linoleic acid, 1,2-DAG denotes 
both 1,2- and 2,3-isomers; C: levels of acylcarnitines. Values are expressed as mean±SE, relative to ―M0 none‖, n = 7–10, representative of 
3 independent experiments. Adapted from [49]. 
 
 
First, we verified that macrophages were polarized well in our experiment. M2 
macrophages are characterized by expression of the enzyme arginase that hydrolyzes arginine 
to ornithine and urea. On the other hand M1 macrophages can synthesize arginine in a cyclic 
fashion while during nitric acid synthesis, arginine is converted to nitric acid and 
citrulline [171]. Therefore high level of ornithine confirmed that macrophages were polarized 
well to M2 form whereas increased level of citrulline bore out the correct M1 polarization 
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(Figure 22 panel A). Also, augmented level of ornithine in case of co-incubation M2 and 
HFF explants showed the shift this polarization marker more toward M2-like metabotype. The 
analogous phenomenon was visible for citrulline in same co-culture, this time represented by 
decreased level of citrulline because it is polarization marker of M1 (Figure 22 panel A). 
Lipolysis of TG results in DG and lately in MG due to several enzymes (for details 
see [172]). Also, glycerol-3-phosphate is starting point of Kennedy‘s pathway, i.e. precursor 
of DG and TG. Our first experiment with RAW macrophages and adipocytes revealed that 
M1 in co-culture with adipocytes had higher levels of glycerol-3-phosphate than M2 with 
adipocytes regardless of adipocytes were from mice fed HF or HFF diet (Figure 23 panel B). 
Same trend was visible for macrophages alone but it was more noticeable when macrophages 
were in co-culture with adipocytes. Further, we denoted higher levels of MG in M2 that were           
co-incubated with adipocytes in compares to M1 with adipocytes (Figure 23 panel D). Both 
results suggest that lipolysis in anti-inflammatory M2 macrophages is under way from TG to 
DG and MG whereas M1 macrophages support lipolysis from TG to DG and vice versa.  
Second experiment with primary macrophages and explants uncovered higher amount 
of MG in M2 with explants. It signifies that M2 provide lipolysis from TG up to MG 
(Figure 22 panel B) and corresponds to the results of previous attempt (Figure 23 panel D). 
This phenomenon was more noticeable when M2 were co-incubated with explants from HFF 
fed animals. We could observe this effect unlike in previous experiment probably due to 
longer time of macrophages in the co-culture. Also, it confirms our hypothesis that beneficial 
effect of omega-3 PUFA is caused by stimulation of M2 macrophages lipid processing. On 
the other hand lower level of MG in M1 signifies that M1 carry out lipolysis from TG to DG 
while there is no changes for M1 with HFF explants. M0 levels were comparable with M1 
levels but we could observe the augmented levels in M0 with HFF explants equally as in M2 
with HFF explants. Results of these two types of experiments indicate that the processes of 
lipolysis and FA re-esterification in M1 are faster and thus it supports higher lipid storage of 
TG in WAT. It is in line with fact that M1 is prevailing in obese individuals [1].  
Also, our outcomes displayed that M2 in co-culture with both types of adipocytes 
contained more acylcarnitines than M1 macrophages with adipocytes. This result indicates 
that M2 use excess of FA to β-oxidation because acylcarnitines are the intermediates of         
β-oxidation [63]. Indeed, level of acylcarnitines was higher when the co-culture was with 
omega-3 PUFA supplemented adipocytes (Figure 23 panel D). It suggests complex 
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stimulation of β-oxidation by omega-3 PUFA. Therefore, the highest β-oxidation is expected 
for co-culture of M2 and adipocytes from HFF fed animals and we confirmed that as well 
(Figure 23 panel D). It corresponds to the fact that M2 as well as omega-3 supplementation 
have beneficial effects on WAT because they utilize FA to β-oxidation rather than storage 
them to TG.   
  
 
Figure 23. Metabolic pathways in M1 and M2 macrophages upregulated by co-incubation with adipocytes from HF and HFF mice. A: 
glutamine to 2-oxoglutarate pathway; B: free FA and glycerol-3 phosphate, starting point of the Kennedy pathway; C: levels of neutral 
lipids; D: lipid degradation and oxidation pathway; E: synthesis of pro-resolving lipid mediators. Values are expressed as mean±SE, n = 8–
16, representative of 5 independent experiments. For the scheme of relevant metabolic pathways and other metabolites, see Figs. S1 and S2, 
respectively. CE, cholesteryl ester; DAG, diacylglycerol; EA, ethanolamine; HDHA, hydroxy-DHA; MAG, monoacylglycerol; TAG, 
triacylglycerol. Adapted from [49]. 
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3.2.4. Conclusion 
 
We utilized our general metabolomic UPLC-MS/MS approach to describe WAT 
metabolism regarding mutual interaction between different cells in WAT. The principal 
finding of this study is that M2 macrophages specifically modulate lipolysis and FA              
re-esterification in WAT of dietary obese mice. Also, our metabolic profiling of macrophages 
revealed that M2 macrophages are under way from triacylglycerol to diaclyglycerol and 
monoacylglycerol whereas M1 macrophages support lipolysis from TG to DG and vice versa. 
Therefore M1 support higher lipid storage of TG in WAT. Of note, we confirmed that M2 as 
well as omega-3 PUFA supplementation have beneficial effects on WAT.     
 
3.3. LIPID MEDIATORS IN DIFFERENT PARTS OF WAT 
 
3.3.1. Introduction 
 
We focused on metabolism of WAT and we utilized several UPLC-MS/MS methods 
to describe main processes there, i.e. lipolysis, FA re-esterification and β-oxidation, as well as 
we determined acylcarnitines as possible biomarkers of obesity, in previous parts of the thesis. 
Here, we wanted to explore another important players in WAT metabolism, i.e. lipid 
mediators. Primary aim of this section was to find how different cell types in WAT modulate 
levels of lipid mediators there. We analysed separately adipocytes, both subfractions of 
stromal vascular fraction (i.e. adipose tissue macrophages and rest of SVF), SVF itself and 
whole WAT by UPLC-MS/MS to achieve this. WAT samples were obtained from mice fed 
HF, HFF or ST diet. Also, we were concentrated on omega-3 PUFA supplementation in diet 
and how it influences pro and anti-inflammatory lipid mediators in WAT. Another goal was to 
explore the effect of omega-3 PUFA on adipose tissue macrophages while they are present in 
WAT due to obesity.  
 
3.3.2. Analytical highlights 
 
General metabolomic LC-MS method. See part 3.1. 
Sample preparation for general metabolomic LC-MS method. See part 3.2. 
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LC-MS method for analysis of eicosanoids and endocannabinoids. See part 3.2. 
Extraction of eicosanoids. First, white adipose tissue with methanol were homogenized in 
bead mill and centrifuged for 5 min. Then standards, cold water, methanol and hydrochloric 
acid were added to samples. Solid phase extraction was done with Strata-X column washed by 
ethylacetate and columns were conditioned with methanol and water. Afterwards samples 
were applied on columns while after both column and sample were washed with water and 
hexane. Importantly, elution of sample was achieved by adding methylformate and methanol. 
Finally, acquired sample was evaporated in Speedvac and residues were dissolved in 
30% acetonitrile and analysed by LC-MS. Second, adipocytes and SVF isolated from WAT 
were extracted same apart from homogenization as well as CD11b positive and CD11b 
negative cells that were separated from SVF. Eicosanoids in macrophages after co-incubation 
were extracted as described in part 3.2.  
 
DNA measurement. DNA was measured in all parts of white adipose tissue and WAT itself. 
DNA was determined using Hoechst fluorescence stain and its concentration was calculated 
using calibration curve prepared with DNA standard.  
 
3.3.3. Results 
 
3.3.3.1. Lipid mediators in WAT 
Initially, we analysed WAT, adipocytes and SVF from mice fed HF, HFF or ST diet. We 
specially focused on protectin D1 (PD1), which is anti-inflammatory lipid mediator that 
improves insulin sensitivity in obese mice, and its precursor 17-HDHA. Cellular origin of 
PD1 and its role in metabolism are not very well explored [104]. Also, PD1 is very sensitive 
to degradation and thus it has to be analysed immediately after collection. As a result, we 
confirmed that levels of lipid mediators PD1 and 17-HDHA were elevated after the        
omega-3 PUFA administration (Figure 24) which is in line with previously published 
data [104]. Measurement of DNA content in WAT ensured that 72% of cells were adipocytes 
and 13% were SVF (data not shown). Measuring DNA is a good measure of total cell number 
due to the invariability of cellular DNA content during even extreme physiological conditions 
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and the excellent correlation with the cell number [173]. Similar levels of 17-HDHA were 
detected both in adipocytes and SVF (Figure 24). Comparing these levels with DNA content 
indicate that SVF is responsible for production of 17-HDHA and PD1 as well. Of note, 
protectin D1 was not detected in isolated adipocytes and although their absolute levels could 
be influenced by collagenase digestion, the distribution pattern responded to levels measured 
in intact WAT. Interestingly, levels of 17-HDHA and PD1 were significantly elevated in 
CD11b negative cells when compared to CD11b positive subfraction, i.e. macrophages, 
(Figure 25 panel A) which is novel finding.  
Our research of lipid mediators further focused on endocannabinoids, specifically two 
best known, anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Both are                     
pro-inflammatory endocannabinoids that are associated with obesity [8]. Our research 
confirmed that amount of 2-AG and AEA were increased after high fat diet feeding in contrast 
to standard diet feeding. On the other hand, omega-3 supplementation counteracted the effect 
of HF feeding in that endocannabinoids (Figure 24) which is in line with findings in obese 
mice [7]. Levels of 2-AG were two orders higher than AEA which is in accord with our 
previous results [174]. Interestingly, levels of 2-AG were similar in adipocytes and SVF. Both 
AEA and endocannabinoid DHEA were detected in WAT and adipocytes but not in SVF 
(Figure 24). It indicates that these compounds have a higher rate of degradation in SVF.   
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Figure 24. Source of lipid mediators in adipose tissue. Epididymal WAT, isolated adipocytes and SVF cells were collected from mice fed 
different diets and lipid mediators were analyzed using LC-MS/MS. 17-HDHA, (±)17-hydroxy-docosahexaenoic acid; protectin D1, 
10R,17S-dihydroxy-docosahexaenoic acid; 2-AG, 2-arachidonoylglycerol; anandamide, N-arachidonoylethanolamine; DHEA, N 
docosahexaenoylethanolamine. x10 e values were multiplied by 10 to fit the range. Values are expressed as mean ± SE, n ¼ 5e7 mice, ng per 
g of source WAT, representative of 2 experiments. *Significantly different from cHF diet. Adapted from [8]. 
 
 
3.3.3.2. Influence of omega-3 PUFA on ATM  
Subsequently, we wanted to explore the beneficial effect of omega-3 PUFA on 
adipose tissue macrophages. Therefore we separated CD11b positive cells (i.e. macrophages) 
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and CD11b negative cells from SVF of mice fed HF or HFF diet. As a result, we denoted that 
CD11b positive cells (i.e. macrophages) had significantly lower levels of arginosuccinate in 
groups supplemented by omega-3 PUFA (Figure 25 panel E). Activation of macrophages 
into M1 metabotype was represented by high levels of arginosuccinate [171] and thus lower 
levels of arginosuccinate in macrophages isolated from HFF adipose tissue indicated that they 
reduced WAT inflammation. It is in agreement with omega-3 PUFA modulation of ATM 
metabolism towards M2 polarization and thus less inflammatory state of tissue (see part 3.2.). 
Also, we revealed that omega-3 PUFA lowered levels of TG while it corresponds to beneficial 
properties of omega-3 PUFA (Figure 25 panel D).  
 
Figure 25. CD11b-positive ATMs in SVF. Concentration of 17-HDHA (A) and protectin D1 (B) in CD11b-positive (empty bars) and CD11b-
negative (black bar) cells isolated from SVF after stimulation with calcium ionophore A23187 (see Fig. 1). *Significantly different levels 
with respect to diets, **significantly different separation according to CD11b marker, p < 0.05, n ¼ 5, means ± SE. Relative levels of oleoyl 
(18:1) ester of cholesterol (C), tri-linoleoyl glycerol (D) and arginosuccinate (E) in CD11b positive (empty bars) and CD11b-negative (black 
bar) cells isolated from SVF. Values as means ± SE relative to cHF, n ¼ 7, representative of 2 independent experiments. Adapted from [8]. 
 
 
3.3.4. Conclusion 
 
Our results showed the interplay between several cell types in WAT. Cell type specific 
production of different lipid mediators was involved in the control of WAT inflammation and 
metabolism. Specifically, we were able to track protectin D1 to SVF cells and confirmed that 
PD1 levels were upregulated by omega-3 PUFA. Surprisingly, the PD1 production was 
associated with CD11b negative cells and not with adipose tissue macrophages.            
Omega-3 PUFA had a beneficial effect on WAT metabolism while we documented here their 
ability to lower the inflammation in WAT.  
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3.4. ANALYSIS OF NOVEL MEMBER OF FAHFA LIPID CLASS  
 
3.4.1. Introduction  
 
Another part of the thesis focused on branched fatty acid hydroxy fatty acids (FAHFA) 
lipid molecules that have probably anti-inflammatory properties and potentially influence 
WAT metabolism as well. We concentrated on novel member of this family, 
i.e. docosahexaenoic acid hydroxylinoleic acid (DHAHLA) that is derived from             
omega-3 PUFA. We utilized UPLC-MS/MS methodology for FAHFA analysis to identify 
DHAHLA compound by its fragmentation scheme and detected several isomers in murine 
serum as well. Another aim was to investigate whether different cell types from WAT could 
synthesize DHAHLA compound. Finally, last goal was to prove the anti-inflammatory 
properties of the analyte of interest.   
 
3.4.2. Analytical highlights 
 
LC-MS method for FAHFA analysis. Branched fatty acid hydroxy fatty acids are 
determined on octadecyl column warmed up to 50 °C. The mobile phase is 30/70 (v/v) 
acetonitrile and water with 0.01% acetic acid, pH 4 (part A) and 50/50 (v/v) acetonitrile and 
isopropanol (part B). Serum samples were analysed by gradient elution in 25 minutes whereas 
structural analysis was done by isocratic elution in 60 minutes. DHAHLA compound is 
measured in negative multiple reaction mode.  
Extraction of FAHFA. First in serum samples, samples were extracted by liquid/liquid and 
solid phase extraction. First LLE, dichlormethane and methanol as organic phase and chilled 
citric acid buffer as water phase were added to sample. After, the organic phase was dried in 
a Speed-vac and dissolved in dichloromethane. SPE was performed on Strata SI-I Silica 
columns conditioned by hexane, sample was applied on columns and elution of FAHFA was 
achieved by ethylacetate. Finally, samples were evaporated, dissolved in methanol and 
analysed by liquid chromatography and mass spectrometry. Cells were homogenized using 
a bead mill at first and then extraction procedure continued as described above. 
Standard of 13-DHAHLA. Standard was synthetized in the Institute of Organic Chemistry 
and Biochemistry of the Czech Academy of Sciences.  
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General metabolomic LC-MS method. See part 3.1. The methodology was utilized to prove 
the anti-inflammatory properties of DHAHLA compound. 
 
3.4.3. Results 
 
3.4.3.1. Methodology for DHAHLA analysis 
The method for FAHFA analysis was optimized by Marie Brezinova and it is 
discussed in her diploma thesis (see [175]). She analysed palmitic acid hydroxystearic acid 
(PAHSA) but the same approach was used for DHAHLA analysis in my project. The 
methodology based on liquid chromatography coupled to hybrid tandem mass with linear ion 
trap spectrometry is described in Methods and Analytical highlights. 
 
3.4.3.2. Fragmentation of  DHAHLA compound 
Mass spectrometer is able to switch from sensitive triple quadrupole scan modes to 
highly sensitive full-scan ion trap mode within one analysis. Therefore, using MS/MS and 
MS/MS/MS technique we were able to reliably identify the structure of docosahexaenoic acid 
hydroxylinoleic acid by its fragmentation scheme (Figure 26 panel A). Specifically, 
DHAHLA was ionized in negative mode to [M-H]
-
 ion m/z 605.457 which is molecular ion. 
Fragmentation by collision-induced dissociation (i.e. MS/MS) resulted in daughter ion        
[13-HLA-H]
- 
m/z 295.228 (Figure 26 panel B). Further fragmentation of that ion in the linear 
ion trap (i.e. MS/MS/MS) gave rise to the ions m/z 179.144 and 195.139, that are specific to 
the position of the hydroxyl group on the hydroxyoctadecadienoic acid (HLA) backbone, 
i.e. 13-DHAHLA (Figure 26 panel C) [111]. Alternatively, specific fragment for                   
9-DHAHLA is m/z 171.10.  
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Figure 26. Analysis of DHAHLA isomers. A: A fragmentation scheme of 13-DHAHLA with 13-HLA-specific fragments. B: MS/MS spectrum 
of 13-DHAHLA. C: Chromatographic profile of DHAHLA isomers (MRM 605.4 > 327.2) detected in murine serum sample (blue line) 
overlaid with synthetic standard of 13-DHAHLA (red line). Inserted table summarizing MS/MS/MS fragments specific to individual 
positional isomers of the hydroxyl group on HLA and MS/MS/MS spectra of 13-DHAHLA. Specific fragments highlighted in magenta. HcLA, 
hydroxy-conjugated-LA. Adapted from [99]. 
 
 
3.4.3.3. DHAHLA analysis in murine serum 
DHAHLA has several isomers [99]. We detected four separated DHAHLA peaks in 
murine serum samples (Figure 26 panel C) by method described previously. Structural 
characterization in the linear ion trap (see above) revealed that 2 major peaks were              
13-DHAHLA and 2 minor peaks were 9-DHAHLA cis-trans isomers of double bonds in HLA 
acyl chains. This is in agreement with the high concentrations of 9(S)- and 13(S)-HODE 
(HLA aka HODE), enzymatic products of 15-lipoxygenase in the organism. Identity of the 
backbone fragmentation was confirmed using synthetic standards for 9(S)-HODE and     
13(S)-HODE.  
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Figure 27. 13-DHAHLA in adipose tissue. A: Levels of 13-DHAHLA in murine epididymal WAT (eWAT), subcutaneous WAT (scWAT) and 
interscapular brown adipose tissue (BAT) with and without omega-3 PUFA supplementation. Black bars, mice on high-fat diet; empty bars, 
mice on high-fat diet supplemented with omega-3 PUFA. Values are expressed as mean ± SE, n=4-8. B: Chromatographic profile of 13-
DHAHLA in naïve 3T3-L1 adipocytes, adipocytes supplemented with 100 µM DHA and LA for 24 hours, and adipocy tes supplemented with 
deuterium-labelled DHA and cold LA for 24 hours, as indicated. Adapted from [99]. 
 
 
3.4.3.4. Cells in white adipose tissue can synthetize DHAHLA 
Generally, branched fatty acid hydroxy fatty acids are released by adipocytes [99,111]. 
We have detected DHAHLA compound in adipose tissue of human and mice (data not shown, 
for details see [99]). The goal of this section was to reveal whether adipocytes and 
macrophages, main parts of adipose tissue, could synthetize DHAHLA. We used in vitro 
models of adipocytes and macrophages treated with DHA and LA to achieve this. 
Specifically, we utilized murine cell model of adipocytes (i.e. 3T3-L1) and human adipocytes 
(i.e. multipotent adipose-derived stem cells, hMADS) and RAW macrophages. DHAHLA 
analyses were performed by method described previously. 
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As a result, we revealed that both types of adipocytes were capable to synthesize 
DHAHLA isomers (Figure 27 panel B, Figure 28). Cell model of macrophages did not 
behave similarly with same level of substrates. Nevertheless when macrophages were exposed 
to higher concentrations of DHA and LA, they were able to synthetize DHAHLA as well 
(Figure 28).  
 
 
Figure 28. Chromatographic profile of 13-DHAHLA in hMADS (adipocytes) supplemented with 10 μM 2H5-DHA and LA for 24 hours, naïve 
RAW 264.7 macrophages and RAW 264.7 macrophages supplemented with 300 μM DHA and LA for 24 hours, as indicated. Adapted from 
[99]. 
 
 
3.4.3.5. Anti-inflammatory and pro-resolving effects of DHAHLA 
PAHSA, a known member of FAHFA family, have anti-inflammatory 
properties [111]. Also, DHA and its metabolites have a beneficial effect on adipose tissue 
inflammation. Thus we hypothesized that DHAHLA could have immunomodulatory 
properties as well. We performed several cell line experiments to prove the anti-inflammatory 
behaviour of DHAHLA compound and we utilized mainly general metabolomics           
UPLC-MS/MS methodology established in part 3.1 for that.  
First, RAW macrophages were stimulated with 100 ng/ml lipopolysaccharide (LPS) to 
activate the macrophages and 10 μM 13-DHAHLA complexed to BSA (in ratio 3:1) was 
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added or not to medium. Then the effect of 13-DHAHLA on cells was analysed by qPCR and 
ELISA measurement. The rate of inflammation is represented by bars of IL-6. Importantly, it 
was shown that DHAHLA prevented the increase pro-inflammatory IL-6 concentrations in 
media (Figure 29 panel A). DHAHLA decreased mRNA levels of inflammatory cytokines 
IL-6, TNF-α, IL-1β and PTGS2 in cells as well (Figure 29 panel A). Therefore it suggests 
that 13-DHAHLA prevented macrophage activation. Further, we wanted to explore the lowest 
effective concentration of 13-DHAHLA that reduces macrophages activation. We used RAW 
macrophages that were stimulated by 10 ng/ml LPS and incubated with different                  
13-DHAHLA concentration for 18 h experiment. As a result, we discovered that 10 nM of     
13-DHAHLA was sufficient concentration that had an effect on cell activation (Figure 29 
panel E).  
Then we utilized murine BMDM that are more relevant to real macrophages in mice 
WAT for another hypothesis. First, an effect of 13-DHAHLA on the stimulation by             
pro-inflammatory cytokine IFN-γ (50 ng/ml) was tested. BMDM were incubated in the 
absence (unstimulated) or presence of IFN-γ (50 ng/ml) with 10 μM 13-DHAHLA. 
Macrophages activation corresponded to the high level of intracellular citrulline and we 
utilized the metabolomic profiling to determinate that metabolite. The level of citrulline was 
decreased after 13-DHAHLA supplementation (Figure 29 panel G) and thus we were able to 
confirm that 13-DHAHLA prevented macrophage activation. Next, FAHFA might serve as 
a pool of FA, and the anti-inflammatory properties of 13-DHAHLA could be partially 
mediated by DHA released via DHAHLA hydrolysis. To test this, BMDM were stimulated 
with 100ng/ml LPS for 18 h and the effects of 10 µM 13-DHAHLA and 10 µM DHA on 
macrophage activation were analysed using metabolipidomics [8,176]. We used the ratio of 
the intracellular concentrations of (citrulline+ornithine)/(arginine+aspartate) to evaluate this 
experiment. The ratio summarizes the intermediates of the related metabolic pathways of 
nitrogen oxide and reactive oxygen species production and it is assumed as the most sensitive 
early marker of macrophage activation [176]. The attempt showed that the pro-inflammatory 
effect of LPS was significantly reduced by both 13-DHAHLA and DHA (Figure 29 panel C). 
It indicates that the effect of DHAHLA can be partially mediated by DHA.  
Afterwards, we carried out experiment with human peripheral blood mononuclear cell 
(PBMCs), another type of immune cells, to test the immunomodulatory potential of              
13-DHAHLA. In practice, freshly isolated PBMCs from buffy coats were preincubated with 
1 mmol/L 13-DHAHLA for 30 min and then exposed to lectin phytohemagglutinin for 
24 hours. Lectin activates T-helper type 1 lymphocytes and also the indoleamine                 
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2,3-dioxygenase (IDO) pathway in macrophages. IDO is the rate-limiting enzyme of the 
essential amino acid tryptophan catabolism toward kynurenine while its activation causes 
tryptophan depletion, reduces the growth of microbes [177], and serves as an immune 
checkpoint [99]. Activation of that enzyme was indicated by a strong increase in the 
kynurenine/tryptophan ratio that was measured in the media. Increased level of 
kynurenine/tryptophan ratio after 13-DHAHLA preincubation confirmed that 13-DHAHLA 
was able to partially prevent IDO activation in PBMCs stimulated with lectin, and to limit 
immunosuppression caused by tryptophan depletion (Figure 29 panel B) [177]. The results 
from experiments with RAW and BMDM macrophages as well as human immune cells 
document that 13-DHAHLA exerts anti-inflammatory and pro-resolving properties. 
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Figure 29. Anti-inflammatory effects of 13-DHAHLA. A: RAW 264.7 macrophages were incubated in the absence (Unstimulated) or 
presence of LPS (100 ng/mL) for 18 h, and the effect of 9-PAHSA (10 mmol/L) and 13-DHAHLA (10 mmol/L) on macrophage activation was 
tested. IL-6 protein levels in the medium, and IL-6, TNF-a, IL-1b, and Ptgs2 mRNA in cells. Values are expressed as the mean ± SE. n = 6, 
representative of three experiments. B: Human PBMCs were freshly isolated from a buffy coat, preincubated with 1 mmol/L 13-DHAHLA, 
and stimulated with phytohemagglutinin (PHA; 10 mg/mL) for 24 h. Levels of tryptophan and kynurenine were measured in the medium. 
Values are expressed as the mean ± SE. n = 8, representative of 3 PBMC isolations. C: BMDMs were incubated in the absence 
(Unstimulated) or presence of LPS (100 ng/mL) for 18 h, and the effect of 13-DHAHLA (10 mmol/L) and DHA (10 mmol/L) on macrophage 
activation was tested. Cells were either extracted for metabolomics (Cit+Orn)/(Arg+Asp) macrophage activation index (relative  fold)—or 
processed for the metabolipidomics of lipid mediators. D: Levels of DHA-derived lipid mediators 17-HDHA, protectin D1, and resolvin D1. 
Values are expressed as the mean ± SE. n = 6, representative of three experiments. N.D., not detected. E: RAW 264.7 macrophages were 
stimulated with LPS (10 ng/mL) and incubated in the presence of various concentrations of 13-DHAHLA for 18 h to explore dosedependent 
inhibition of macrophage activation. The LPS-stimulated state is set as a reference point. Values are expressed as the mean ± SE. n = 6, 
representative of two experiments. F: BMDMs were pretreated for 15 min with 13-DHAHLA, as indicated, and were incubated with 
fluorescein labelled zymosan for 30 min. Extracellular fluorescence was quenched with trypan blue and fluorescence measured using a plate 
reader. Values are expressed as the mean ± SE. n = 8, representative of three experiments. G: BMDMs were incubated in the absence 
(Unstimulated) or presence of IFN-g (50 ng/mL) for 18 h, and the effect of 13-DHAHLA (10 mmol/L) on macrophage activation 
(intracellular citrulline levels) was tested. Values are expressed as the mean ± SE. n = 6. *P < 0.05. Adapted from [99]. 
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3.4.4. Conclusion 
 
To summarize it, our metabolipidomic methodology using UPLC-MS/MS enabled us 
to identify novel compound of FAHFA lipid class derived from DHA and LA, 
i.e. docosahexaenoic acid hydroxylinoleic acid. Also, we detected several isomers of that 
compound in murine serum. Our cell line experiments elucidated that DHAHLA were 
synthetized by adipocytes and macrophages in WAT. Also, this substance was involved in the 
beneficial anti-inflammatory effects attributed to omega-3 PUFA and therefore DHAHLA 
may improve the metabolism of adipocyte in obesity [99].  
 
3.5. ANALYSIS OF DHAHLA COMPOUND IN MILK SAMPLES 
 
3.5.1. Introduction 
 
Synthesis of FAHFA is linked with de novo lipogenesis [111] which is tightly regulated in 
the lactating human mammary gland [178]. Previously, we have quantified the amount of 
docosahexaenoic acid hydroxylinoleic acid (DHAHLA), novel compound of FAHFA family 
with anti-inflammatory and anti-diabetic properties, in human and mice WAT and plasma 
samples (data not shown, for details see [99]). Here, we continued with analysis of DHAHLA 
compound presented in previous section but this time in human breast milk where we 
hypothesized should be found for the first time. Then we focused whether FAHFA in breast 
milk could appear in the circulation of infants. This type of experiment is problematic due to 
ethical reasons and thus we performed mice experiment to explore that.  
 
3.5.2. Analytical highlights 
 
LC-MS method for FAHFA analysis. See part 3.4. 
Extraction of FAHFA in milk samples. Extraction in milk samples is slightly different than 
extraction in serum samples. First, milk samples were warmed to 25 °C in water bath and 
homogenized for 10s in ultrasonic bath. Later on, LLE with dichlormethane, methanol and 
citric acid buffer was performed as described before. The organic phase was collected, water 
phase was re-extracted and then organic phase was pooled, dried in a Speed-vac and dissolved 
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in dichloromethane. After that solid phase extraction was performed on Hypersep columns. 
FAHFA were eluted from SPE columns with ethyl acetate as previously and they were 
concentrated using Speed-vac, dissolved in methanol and analysed by LC-MS.  
 
3.5.3. Results 
 
3.5.3.1. Analyses of milk sample 
LC-MS/MS analyses of milk samples were done as FAHFA analyses before (for 
details see part 3.4.). We discovered FAHFA composition of human milk (data not shown, for 
details see [179]). The compound 13-DHAHLA was also found in human breast milk but only 
in samples from mothers who were supplemented with omega-3 PUFA during pregnancy 
(Figure 30). It is in line with finding that synthesis of DHA-derived FAHFA depends on 
omega-3 PUFA intake.  
 
Figure 30. Profile of 13-DHAHLA in human milk. MRM profile of 13-DHAHLA in breast milk from a single mother who reported omega-3 
PUFA supplementation during pregnancy. Adapted from [179]. 
 
 
3.5.3.2. Bioavailability of orally administrated FAHFA  
Mice were gavaged by 5-PAHSA or not for three days to reveal the bioavailability of 
orally administrated PAHSA. Then levels of that compound were determined in mice plasma. 
As a result, we uncovered that administration of 5-PAHSA elevated its level in mice plasma 
(Figure 31) while it suggests that PAHSA from breast milk might reach newborn´s 
circulation.   
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Figure 31. Bioavailability of digested 5-PAHSA. Male mice were gavaged with 5, 10, and 20 mg 5-PAHSA/kg body weight or an equivalent 
volume of vehicle (50% PEG400, 0.5% Tween-80, 49.5% H2O [180] once daily for 3 days, followed by the analysis of 5-PAHSA levels in 
plasma. Data are expressed as mean ± S.E., n = 3. Adapted from [179]. 
 
 
3.5.4. Conclusion 
 
To sum up this part, we detected DHAHLA compound in human breast milk for the 
first time while it has been only reported in human serum and adipose tissue previously. Also, 
our animal´s experiment suggests that administration of FAHFA analytes may reach infants´s 
circulation and thus potentially positively influence their metabolism.   
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4. SUMMARY 
 
This dissertation thesis is focused on adipose tissue metabolism. Firstly, we wanted to 
find and optimize UPLC-MS/MS methods for the analysis of acylcarnitines (AC) and amino 
acids (AmA), because these metabolites are associated with obesity and they are important 
diagnostic markers. We also aimed to find new AC or AmA biomarkers with propensity to 
obesity in animal experiments using these platforms. The first method used for analysis of 
acylcarnitines and amino acids was based on the HILIC column and was able to separate 
57 AC and 21 AmA in less than 10 minutes. Moreover, the method was validated with good 
precision and accuracy up to 11 %. Importantly, these analyses enabled us to separate isobaric 
species C4OH and C3DC which is not usually possible. We utilized this approach in mice 
experiment where we identified several acylcarnitines, i.e. long chain ACs, carnitine, 
acylcarnitines C4 and C6, C4DC, as well as amino acids, i.e. tyrosine, alanine, ornithine and 
threonine, that could serve as complex, gender-specific biomarkers of propensity to obesity 
and partially also as a biomarker of obesity-associated insulin resistance. Afterwards, we 
adapted the UPLC-MS/MS general metabolomic method with an aminopropyl column that 
allowed us to separate as many as 254 metabolites including AC and AmA in 40 minutes. 
This simplified the peak integration process in comparison to the AC´s and AmA´s 10minutes 
method. We utilized this platform in an experiment using rats where we discovered that 
maternal intake of a cafeteria diet during lactation entails an alteration in the plasma profile of 
AC and AmA. Specifically, changes were apparent in their offspring in the case of C2 and 
medium- and long-chain AC, as well as in the case of glycine, alanine, isoleucine, serine and 
proline.   
Next, we utilized mainly the general metabolomic UPLC-MS/MS method established 
before to explore adipose tissue metabolism regarding mutual interactions between main cell 
types of adipose tissue, i.e. adipocytes and adipose tissue macrophages. We were especially 
interested in the effect of omega-3 PUFA on that interaction. The co-culture experiment with 
adipocytes and macrophages showed that macrophages modulate lipolysis and FA                 
re-esterification in adipocytes while this effect depends on the polarization state of 
macrophages and their response to dietary omega-3 PUFA supplementation. Moreover, the 
metabolic profile of adipocytes is not significantly altered by co-incubation with macrophages 
but macrophages react dynamically to the presence of adipocytes. Our analyses showed that 
inflammatory M1 and anti-inflammatory M2 macrophages act differently. For example, 
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lipolysis in M2 macrophages happens from TG to DG and MG whereas lipolysis in M1 
macrophages occurs only from TG to DG and vice versa. Thus, M1 macrophages store fatty 
acids in neutral lipids whereas M2 use them for β-oxidation. Of note, omega-3 PUFA further 
support β-oxidation. The results confirmed our hypothesis that the beneficial effect of     
omega-3 PUFA is caused by stimulation of M2 macrophages lipid processing and that M2 
macrophages specifically modulate lipolysis and FA re-esterification in adipose tissue of 
dietary obese mice.  
Subsequently, we concentrated on lipid mediators that are produced in white adipose 
tissue (WAT) and their effect on adipose tissue metabolism. Specifically, we studied how 
different cell types in WAT modulate levels of lipid mediators and how omega-3 PUFA affect 
them. Our results showed the interplay between several cell types in WAT and cell type 
specific production of different lipid mediators that is involved in the control of WAT 
inflammation and metabolism. In addition, we were able to find the origin of                       
anti-inflammatory lipid mediator protectin D1 and determined several endocannabinoids in 
different cell types of adipose tissue. Importantly, we confirmed that adipose tissue 
macrophages isolated from WAT supplemented by omega-3 PUFA are able to reduce WAT 
inflammation. Beneficial properties of omega-3 PUFA were documented by lowered levels of 
TG in adipose tissue.  
Another part of this thesis focused on FAHFA lipid molecules that have strong       
anti-inflammatory properties and potentially influence WAT metabolism. We identified 
a novel compound of this family, docosahexaenoic acid hydroxylinoleic acid (DHAHLA) 
which is derived from omega-3 PUFA. We utilized MS/MS and MS/MS/MS techniques to 
identify its structure by fragmentation scheme and UPLC-MS/MS methodology to detect 
several isomers of DHAHLA in murine serum. We have detected 13-DHAHLA in adipose 
tissue and therefore were interested in whether adipocytes or macrophages, the main parts of 
adipose tissue, could synthetize DHAHLA. As a result, the cell lines of adipocytes are able to 
synthesize 13-DHAHLA as well as macrophages but with a higher concentration of substrates 
in this case. We mainly utilized the general metabolomic UPLC-MS/MS approach established 
before to explore the potential anti-inflammatory properties of the 13-DHAHLA compound. 
The outcome from cultured cell experiments showed that 13-DHAHLA exerts                     
anti-inflammatory and pro-resolving properties. We found that 10 nM 13-DHAHLA is the 
lowest effective concentration that reduces activation of macrophages. Our attempt also 
indicated that the anti-inflammatory effect of 13-DHAHLA could be partially mediated by 
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DHA released from DHAHLA via hydrolysis. Later on, we hypothesized that 13-DHAHLA 
could be found in human milk. The compound was truly discovered but only in samples from 
mothers who were supplemented with omega-3 PUFA during pregnancy. Of note, we 
performed experiment on mice suggesting that FAHFA from breast milk reach a newborn‘s 
circulation.    
To sum up, we concentrated on adipose tissue metabolism and we utilized several 
UPLC-MS/MS methods to describe the main processes in adipose tissue - lipolysis, FA        
re-esterification and β-oxidation. Moreover, we analysed different compounds that influence 
adipose tissue metabolism, specifically, acylcarnitines, amino acids as well as lipid mediators 
and FAHFA compounds. We performed mainly experiments on mice and cell line to achieve 
our goals. All the experiments included omega-3 PUFA supplementation because it has 
a beneficial metabolic effect on adipose tissue and we tried to clarify its effect on this over 
a long term period. 
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